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1. INTRODUCTION
1.1. Drug delivery system 
The  treatment  of  acute  diseases  or  chronic  illness  has  been  achieved  by
delivery of drugs to the patients for many years. These drug delivery systems include
tablets, injectables, suspensions, creams, ointments, liquids and aerosols. Today these
conventional drug delivery systems are widely used. The term drug delivery can be
defined as techniques that are used to get the therapeutic agents inside the human
body (Loyd et al., 2006).
Another role of the drug delivery systems is to allow the safe application of
the  drug.  This  includes  that  the  drug  on  the  formulation  must  be  chemically,
physically and microbiologically stable. Side-effects of the drug and drug interactions
should be avoided or minimized by the use of suitable drug delivery systems. The
delivery  systems  also  need  to  improve  the  patient’s  compliance  with  the
pharmacotherapy  by  the  development  of  conventional  applications   (Lee  and
Robinson, 2000). For example, one can improve patient compliance by developing an
oral dosage form where previously only par-enteral application was possible. Finally,
the delivery system needs to be reliable and its formulation needs to be technically
feasible. This means the pharmaceutical quality of the delivery systems needs to be
absurd, drug release from the system needs to be reproducible and the influence of the
body on drug release  should  be  minimized (  for  example,  food  effects  after  oral
administration).  Drug delivery system is broadly classified into two types they are
(Saptarushi D & Mukul S, 2009).
A. Conventional drug delivery systems.
B. Modified drug delivery systems.
A. Conventional drug delivery system 
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Conventional  drug  therapy  requires  periodic  doses  of  therapeutic  agents.
These  agents  are  formulated  to  produce  maximum  stability,  activity  and
bioavailability.  For  most  drugs,  conventional  drug delivery is  effective,  but  some
drugs  are  unstable  or  toxic  and  have  narrow  therapeutic  window  and  solubility
problems  (Leon  lachman  et  al.,  1986).  In  such  cases,  a  method  of  continuous
administration of therapeutic agent is desirable to maintain fixed plasma levels. This
continuous  drug delivery can  be  achieved  by the  use  of  controlled  drug  delivery
systems.  These  delivery  systems  have  a  number  of  advantages  over  traditional
systems  such  as  improved  efficiency,  reduced  toxicity  and  improved  patient
convenience.  The main goal  of  modified drug delivery systems is  to  improve the
effectiveness of drug therapies  (Howard C et al., 2000).
Conventional  dosage  forms  are  rapidly  absorbed,  with  the  ascending  and
descending portions of the concentrations versus time curve reflecting primarily the
rate of absorption and elimination, respectively (Aulton M.E, 2000). Because of the
rapid rate of absorption and elimination from conventional dosage forms, drugs are
usually administered more than once daily, with the frequency being dependent on
biological half life (t1/2) and duration of pharmacological effect. The time of dosing
may also be effected by therapeutic index of a drug  (Schwartz BJ, 2000).
 Limitations of conventional drug delivery systems 
 In conventional oral dosage forms, there is little or no control over the release of the
drug and effective concentration at  the target  site can be achieved by intermittent
administration of glossy excessive doses.
Department  of pharmaceutics               2               JKKMMRF college of pharmacy
Chapter 1                                                                                                   Introduction
 The  dosing  pattern  in  conventional  dosage  forms  results  in  constantly  changing,
unpredictable and often sub-therapeutic plasma concentrations, leading to marked side
effects in some cases. 
 The rate and extent of absorption of drug from conventional formulations may vary
greatly,  depending on the factors  such as  physicochemical  properties  of  the drug,
presence of excipients, various physiological factors such as the presence or absence
of food, pH of the Gastrointestinal tract, Gastrointestinal motility and so on. 
 Poor patient compliance, increased chances of missing the dose of a drug with short
half-life for which frequent administration is necessary. 
 The unavoidable fluctuations of drug concentration may lead to under medication or
over medication. 
 A typical  peak-valley  plasma  concentration-time  profile  is  obtained  which  makes
attainment of steady-state condition difficult.
 The fluctuations in drug levels may lead to precipitation of adverse effects especially
of a drug with small Therapeutic Index (TI) whenever over medication occur (Peter
ridgeway et al., 2001). 
B. Modified Drug Delivery System 
Dosage forms can be designed to modify the release of the drug over a given
time after the administration or for a prolonged period of time or to a specific target in
the body. Modifications in drug release are often desirable to increase the stability,
safety and  efficacy of  the  drug,  to  improve  the  therapeutic  outcome of  the  drug
treatment  and  to  increase  patient  compliance  and  convenience  of  administration
(William Andrew,  Wise and Donald L, 2000).
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 Classification
Modified Release dosage form may be classified as
A. Delayed Release
B. Extended Release 
i. Sustained Release
ii. Controlled Release
A. Delayed Release 
A Delayed Release dosage form is designed to release the drug at a time other
than  promptly after  administration.  Dosage  forms  can  be  designed  to  modify the
release of the drug over a given time or after the dosage form reaches the required
location.
Delayed Release oral dosage forms can control where the drug is released, e.g.
when the dosage form reaches the small intestine (enteric-coated dosage forms) or the
drug after a predetermined time in a predetermined location, i.e. they do not release
the drug immediately after  ingestion,  for  example enteric-coated tablets,  pulsatile-
release capsules. The oral route of drug delivery is typically considered the preferred
and most patient-convenience means of drug administration. The release of drug from
an  oral  dosage  form  may  be  intentionally  delayed  until  it  reaches  the  intestine
(Brahmankar D M & Jaiswal S B, 1995).
The correct selection and balance of excipients and processes in solid dosage
formulations  are  designed  either  for  improving  the  micrometric  or  macro  metric
properties  of  materials  during  manufacture  and/or  for  providing  a  desired  drug
delivery system. The mostly commonly used pharmaceutical  delayed release solid
oral dosage forms today include tablets, capsules, granules and pellets.
Figure 1: Delayed dosage form compared to an immediate-release dosage form
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tmaxIR is the time for maximum plasma concentration of the drug released from an
immediate-release  dosage  form  and  tmaxDR is  the  time  for  maximum  plasma
concentration of the drug released from a delayed-release dosage form (Chein Y.W,
1992).
 Significance of delayed release systems
The design of  such system involves release of drugs only at a specific site in
the gastrointestinal tract. The drugs contained in such a system are those that are:
 Destroyed in the stomach by enzymes 
 Known to cause gastric distress 
 Absorbed from a specific intestinal site 
 Meant to exert local effect at a specific gastro-intestinal site.
B.  Extended release drug delivery system 
Extended release system was introduced in the pharmaceutical market in the
early 1950s by Smith Kline and French made an orally administered formulation of
Dextroamphetamine  sulphate  by incorporating  the  drug  pellets  coated  with  wax.  
Extended  release  dosage  forms  release  drug  slowly,  so  that  plasma
concentrations are maintained at a therapeutic level prolonged period of time (usually
12hrs)  extended  drug  action  at  a  pre-determined  rate  by  maintaining  a  relative
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constant, effect drug level in the body with concomitant minimization of undesirable
side effects that are associated with a saw tooth kinetic pattern of conventional release
(Remington, 2002).
The terms sustained release, time release, prolong release or extended release
are used to identify drug delivery systems that are designed to achieve a prolonged
therapeutic blood or tissue levels of the drug by continuous release of the extended
period of time after administration of a single dose (Mankar et al., 1999).
Extended release tablets and capsules are commonly taken only once or twice
daily.  Typically  extended  release  products  provide  an  immediate  release  of  drug
which  promptly  products  the  desire  therapeutic  effect  which  then  is  followed  by
gradual and continual release of additional amounts of drug to maintain this effect
over a pre-determined period of time. The sustained plasma drug levels provide by
extended  release  drug  products  often  eliminate  the  need  for  night  dosing,  which
provides benefit to the patient.
Reasons for developing extended release drug delivery system
Immediate release of the active ingredient with resulting fast absorption rate
may not  always  be  desirable.  If  the  drug  has  narrow therapeutic  index,  fast  and
complete  absorption may result  in  plasma concentration  that  corresponds  to  toxic
levels.
Advantages
 Improved patient compliance
 Less frequent dosing (by reducing number of doses) 
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 Reduced patient care time
 Decreased local and systemic side effects 
 Reduced Gastrointestinal irritation and other dose related side effects
 Improved efficiency in the treatment
 Optimized therapy
 More uniform blood concentration 
 Reduction in  fluctuation in  drug level  and  hence  uniform pharmacological
response.
 Cure or control of condition more promptly 
 Reduction  in  the  incidence  and  severity of  untoward  systemic  side  effects
related to high peak plasma drug concentrations
 Maintenance  of  the  therapeutic  action  of  a  drug during overnight  no  dose
period
e.g.:  Overnight  management  of  pain  in  terminally  ill  patient’s  permits
improved sleep.
 Employ less total drug.
 Minimum drug accumulation on chronic dosing 
Disadvantages
 They are costly
 Dose dumping
 Increased variability among dosage units. 
Figure 2: Plasma drug concentration profiles for conventional tablet or capsule
formulation and extended release (sustained and controlled) formulation.
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A. Sustained release dosage forms
Sustained release technologies can improve the therapeutic efficacy and safety
of a drug by precise temporal and spatial placement in the body, thereby reducing
both the size and number of doses required. Furthermore, the possibility of repeating
successful drugs, coupled with the increasing expense in bringing new drug entities to
market,  has  been  instrumental  in  generating  interest  in  sustained-release  dosage
forms.
The sustained release dosage form is defined as “any drug or dosage form
modification that prolongs the therapeutic activity of the drug”. Once the maximum
level is reached, the amount of drug in the body decreases slowly so it will take longer
to drop below the therapeutic range. 
The  terms  sustain  or  controlled  drug  release  incorporates  the  element  of
prolongation  of  duration  of  drug  action  as  well  as  the  drug  predictability  and
reproducibility in drug release kinetics. Polymeric sustained drug delivery systems
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offer  numerous  advantages  when  compared  with  conventional  dosage  forms,
including improved efficacy, reduced toxicity, and improved patient compliance.
B. Controlled drug delivery 
Controlled drug delivery of drug s delivery of drug at a rate or at a location
determined by needs of body or disease state over a specified period of time (Chein Y.
W, 1989).
Figure 3: Dissolution profile of controlled release dosage form.
The release system is formulated to dissolve slowly and release a drug over
time. The main advantage of controlled release tablets and capsules are that they can
often less frequently than instate release formulations (Brahmankar D M, 1995).
There are certain conditions for the formation of controlled release formulation:
1. If the active compound has a long-life (over 6hrs), it is sustained on its own.
2. If the active compound has a short long-life it would require a large amount to
maintain a prolonged effective dose. 
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3. In  case  of  broad  therapeutic  window,  it  is  necessary  to  avoid  toxicity,
otherwise, the risk is unwarranted and another mode of administration would
be recommended.
The basic goal of controlled drug delivery system is to achieve a steady blood
or tissue level of a drug at a specific site, which will be therapeutically effective and
non-toxic.  The enteric  coated pellets and tablets deliver the drug almost at  a  pre-
determined rate locally for a specified period of time at a specific site by reducing
adverse effect. When compare with the other conventional dosage forms like tablets
or capsules the maximum administration dose is very fewer amounts after maximum
administration  of  dose  it  will  cause  toxicity.  Such  type  of  active  pharmaceutical
ingredients is administered by extended release preparations. The bioavailability of
drugs is more when compare with the tablets surface area of the pellets is more. In
case of tablet coating uniform coating is not occurred dose dumping will occur, in
case pellets if any pellet is not coated well the effect will be minimized by the other
pellets for that only pelletization is more effective preparation.
Biopharmaceutical drug classification 
Class I:  High solubility- High permeability
Class II: Low solubility- High permeability
Class III: High solubility- Low permeability
Class IV: Low solubility- High permeability
The above classification is mainly by taking the solubility and permeability
characters of the drug into the consideration. This is the most acceptable classification
of the drugs in the pharmaceutical industry. The present drug has high solubility and
permeability characteristics. Solubility and permeability play an influential role in the
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performance or conventional products (Lee et al., 2001). Their role is even greater in
extended release systems. The present drug i.e Metoprolol succinate belongs to the
class I (Lordi N. G. 1991 & Robinson R & Lee V. H 1995).
The below factors also play a key role in extended release systems (Kinam P et al.,
2009).
1) Aqueous solubility and Pka
2) Partial ion co-efficient
3) Drug stability 
4) Molecular size
5) Rate of diffusion
6) Protein binding.
Capsules
Capsules are solid dosage forms in which the drug or a mixture of drugs are
enclosed in hard or soft gelatin capsules. These shells are made up of gelatin and are
available in various sizes, shapes and capacity.
Types of capsules
1) Hard gelatin capsules
2) Soft gelatin capsules
3) Sustained release capsules
4) Enteric capsules
Capsules evaluation tests and standards
1. Description
The color, size and shape of the capsules are examined visually and
they  are  reported.  The  color,  size  and  shape  of  the  capsule  should  be
acceptable  by  the  patient  and  should  be  conveniently  taken  up  by  the
patient i.e. the capsule dosage form should be palatable.
2. Content of active ingredients (Assay)
The assay is done to check the drug content in the formulation and to
indentify whether it complies with the specified limits that are specified. 
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Limit:- 90 to 110% of label claim or as per in house limit.
3. Uniformity of weight
This  evaluation  test  is  done  to  know  whether  all  the  formulations
consists of the same amount of drug  (Park, 2009).
Table 1: Standard values for uniformity weight of capsules
Average weight of capsules Percentage deviations
Less than 300 mg 10%
300 mg or more 7.5%
4. Disintegration test
 The  disintegration  test  is  done  to  know  the  time  needed  for  the
disintegration of the capsule shells and to release its components  into the
buffer solution.
Hard gelatin capsules: Disintegration time shall not be more than 30 min.
Soft gelatin capsules: Disintegration time shall not be more than 60 min.
Enteric capsules:  Acidic media- shall not disintegrate in 2 hrs
          Basic media- shall disintegrate within 30 min.
5. Standard length for hard gelatin capsules in “mm”
Table 2: Standard length of hard gelatin capsules
Siz
e
Cap Body
0 10.68-11.68 18.22-19.22
1 9.51-10.51 16.22-17.2
2 8.67-9.67 14.84-15.84
3 7.73-8.73 12.98-13.98
4 6.97-7.97 11.84-12.84
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6. Microbial limits 
      This is checked to identify any microbial content in the capsule shell.
The standard limit  for  the  microbial  content  is  NMT 1000 ppm/gm of
capsules shell.
7. Loss on drying
 The loss on drying is measured to know the moisture content in the
mixture  and  it  is  also used  to  know the  weight  of  the sample  without
moisture. Between 12.5% and 16% detrained on 0.3 gm of shall by drying
in oven at 105°C for 4 hrs at constant weight.
Reason for selecting capsules
The Metoprolol succinate is available in tablet form, the research is going on
to formulate an efficient capsule dosing form due to its advantages over the tablet
dosage form. It should be kept in mind that pharmaceutical compositions formulated
in  tablets  are  subject  to  variations  in  their  physicochemical  properties  such  as
hardness, disintegration time and dissolution time and also on dissolution rate due to
the compression process involved in their production. Such variations are of course
undesirable in extended release Metoprolol succinate capsules, since the prediction of
the  dissolution  rate  is  an  extremely  important  factor  for  the  efficiency  of  the
formulation.  Finally extended  release  multi-particulate  formulations  of  Metoprolol
Succinate provide a better drug release at the gastro-intestinal tract compared with
single tablet formulations.
Pellets
Definition  
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pellets can be defined as small, free flowing, spherical or semi-spherical solid
units,  typically  from  about  0.5mm  to  1.5mm,  and  intended  usually  for  oral
administration, manufactured by the agglomerates of fine powders or granules of bulk
drugs and excipients using appropriate equipment (Gennrao R A, 2009). Pellets can be
prepared by many methods, the compaction and drug layering being the most widely
used today (Cleland J.L & Langer R, 1997).
Regardless of which manufacturing process is used, pellets have to meet the
following requirements. 
1. They should be near spherical  and have a smooth surface; both considered
optimum characteristics for subsequent film coating.
2. The particle size range should be as narrow as possible. The optimum size of
pellets for pharmaceutical use is considered to be between 600 mm and 1000
mm.
3. The pellets should contain as much as possible of the active ingredient to keep
the size of the final dosage form within reasonable limits. 
Significance of pellets
Pellets may have varied applications in varied industries. It  just requires an
innovative bend to use it to derive maximum profitability. The smooth surface and the
uniform size of pellets allow uniform coating not only for each pellet but also from
batch to batch.
Highlighted  below  are  some  of  the  few  instances  where  smooth  surfaced
uniform pellets are successfully used:
1. Improved appearance of the products.  Coating of  pellets  can be done with
different drugs to enable a controlled release rate.
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2. In case of immediate release products larger surface area of pellets enables
better distribution.
3. Chemically incompatible products can be formed into pellets and delivered in
a single dose by encapsulating them.
4. In the chemical industries it is used to avoid powder dusting.
5. Varied applications are possible in the pellet form. Example: sustained release,
controlled release, immediate release and etc..
6. Pellets  ensure  improved  flow  properties,  and  flexibility  in  formulation
development and manufacture.
7. The coating material may be colored with a dye material so that the beads of
different coating thickness will be darker in color and distinguishable from
those having fewer coats.
8. The beads or granules of different  thickness of coatings are blended in the
desired proportions to give the desired effect.
9. The thickness of the coat  on the pellets dictates the rate  at  which drug or
contents are released from the coated particles. A smooth surface of the pellets
and uniform coating thickness for each pellet.
10. By selecting  the  proper  formulation,  processing  conditions  and  processing
equipment it is possible to attain smooth surfaced and uniform pellets.
Advantages of pelletization  
1. Improved appearance of the product and the core is pharmaceutically elegant.
2. Pelletization offers flexibility in dosage form design and development.
3. Pellets are less susceptible to dose dumping.
4. It reduces localized concentration of irritative drugs.
5. It improves safety and efficacy of a drug.
6. Pellets offer reduced variation in gastric emptying rate and transit time.
7. Pellets disperse freely in G.I.T and invariably maximize drug absorption and
also reduce peak plasma fluctuation.
8. Pellets ensure improved flow properties in formulation development.
9. They flow freely and pack easily without significant difficulties, resulting in
uniform and reproducible fill weight of capsules.
10. In the chemical industries it is used to avoid powder dusting.
11. In case of immediate release products larger surface area of pellets enables
better distribution.
Department  of pharmaceutics               15               JKKMMRF college of 
pharmacy
Chapter 1                                                                                                   Introduction
12. Chemically incompatible products can be formed into pellets and delivered in
a single dose by encapsulating them.
13. Varied applications are possible in the pellet form. Example: sustained release.
14. The thickness of the coat on the pellets dictates the rate at which the drug or
contents are released from the coated particles. A smooth surface of the pellets
and uniform coating thickness for each pellet provides a good release.
15. The coating material may be colored with a dye material so that the beads of
different coating thickness will be darker in color and distinguishable from
those having fewer coats.
The most important reason for the wide acceptance of multiple unit products is
the rapid increase in popularity of oral controlled release dosage forms, Controlled
release oral solid dosage forms are usually intended either for delivery of the drug at a
specific site within the GIT or to sustain the action of drugs over an extended period
of  time.  With  pellets,  the  above  mentioned  goals  can  be  obtained  through  the
application of coating materials (mainly different  polymers),  providing the desired
function or through the formulation of matrix pellets to provide the desired effect. The
advantage of multiple unit products as a controlled release dosage form is believed to
be their behavior in-vivo because of their advantageous dispersion pattern in the GIT
and their special size characteristics (Vyas S.P & Khar R K, 2002).
Product characteristics
 Dust free
 Round pellet
 Good flow behavior
 Easy to dose 
 Compact structure
 Low hygroscopicity
 High bulk density
 Dense, uniform surface
 Narrow grain size distribution
 Low abrasion
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 High active ingredient content is possible 
 Optimum starting shape for subsequent coating
 Theory of pellet formation 
In  order  to judiciously select  and optimize any pelletization or granulation
process,  it  is  important  to  understand  the  fundamental  mechanisms  of  granulate
formation  and  growth.  Different  theories  have  been  postulated  related  to  the
mechanism of formation and growth of pellets. As the conventional granulation, the
most  thoroughly  studied,  most  classified  pelletization  process,  which  involves  a
rotating  drum,  a  pan  or  a  disc,  has  been  divided  into  three  consecutive  regions:
nucleation, transition and ball growth, the following steps were proposed: nucleation,
coalescence, layering and abrasion transfer (Chein Y.W, 1989).
Methods of preparing pellets
Compaction  and  drug  layering  are  the  most  widely  used  pelletization
techniques in the pharmaceutical industry. Of the compaction techniques, extrusion
and  spheronisation  is  the  most  popular  method and  in  drug  layering  the  wurster
process is most widely used. Recently melt pelletization has been used frequently in
making compaction pellets using a different type of equipment, for example: a high-
shear mixer. Other pelletization methods such as globulation, balling and compression
are also used in development of pharmaceutical pellets but in a limited scale.
Figure 4: Layered pellet internal characteristics and layered pellet
.                                      
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A. Powder layering
In  this  technique the dry powders  of  the drug an  its  excipients are  mixed
thoroughly and they are deposited as the successive layers over the inert core. the
binding liquids are used for the deposition of the dry powder layers.  This process
takes place mostly in a specialized equipment known as the spheroniser. The container
should be made of solid walls. There should be no perforations in the container walls.
The walls should be of smooth in texture so that the powder should not be attached to
the walls of the container.
Figure 5: Powder layering
B. Solution/suspension layering
In this technique the drug along with its excipients are weighed accurately and
are mixed in a solution to form a uniform suspension. Then this mixture is coated on
the inert core materials. The coating should be done in such a way that the inert cores
are  uniformly  coated  with  the  drug  suspension.  this  process  involves  mainly  the
wurster  process.  These  involves  the  equipments  such  as  coating  pans,  centrifugal
granulators and fluidized bed processors. mostly the inert core material used is the
Department  of pharmaceutics               18               JKKMMRF college of 
pharmacy
Chapter 1                                                                                                   Introduction
sugar spheres. The efficiency of the process and the quality of the pellets produced are
related to the type of equipment used and the conditions or parameters that are used
during the coating process.
Figure 6: solution or suspension layering
C. Pelletization by extrusion and spheronisation 
In this process the drug along with its excipients are taken and mixed together
to form mass. Then these are converted to form the extrudes  through the process
extrusion and  then  these  are  converted  into  small  beads  like  structures  through a
process known as spheronisation. Nowadays equipments are available by which both
the  extrusion  and  spheronisation  are  done  simultaneously  in  a  single  equipment.
Through his process beads as fine as 0.6 mm can be obtained (Gibson, 2009).
Figure 7: Pelletization by spheronisation and extrusion
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D. Other methods
Other pelletization methods such as globulation, cryo-pelletization, balling and
compression are also used, although these are used for a limited scale of preparation
of pharmaceutical pellets in the pharmaceutical industry.
Globulation
This involves both the spray drying and spray congealing processes. In this
process  the  drug  is  mixed  with  its  excipients  and  is  converted  into  a  uniform
suspension  by  using  a  suitable  vehicle.  Then  this  solution  is  taken  into  special
equipment where the drug suspension is sprayed in the form of fine particles and hot
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air is blown from the bottom by which the fine droplets are condensed and dried and
forms small particles known as pellets.
Spray congealing
In this process the drug is mixed with its excipients and is converted into a
uniform suspension by using a suitable vehicle. Then this solution is taken into special
equipment where the drug suspension is sprayed in the form of fine particles and hot
air is blown from the bottom by which the fine droplets are condensed and dried and
forms small particles known as pellets. Both immediate and controlled release pellets
can be prepared in this process by taking the ingredients of different physicochemical
and altering the other formulation variables.
Cryo - pelletization 
In this process the drug is mixed with the required excipients and if formed
into a suspension or solution form. Then this solution form or suspension form is
spayed and is converted into spherical particles and allowed to pass through the liquid
nitrogen  medium.  Then  the  spherical  particles  are  condensed  to  form  into  solid
particles. The liquid nitrogen is used as the fixing medium. The shape of the spherical
particles depends on the distance travelled by the suspension before coming in contact
with the liquid nitrogen. 
Compression
This is the simple process in developing the pellets. this process involves the
mixing  of  the  drug  and  its  excipients  and  the  they  are  compressed  to  form the
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condensed products. This is one of the compaction technique. The process variables
which control  the quality of tablets is  similar to the preparation of pellets by this
process.
Balling
In this process, the drug along with its excipients are taken and they are mixed
thoroughly. Then they are placed in the pans or discs with continuous circular motion.
When the drug mixture along with its excipients are placed in these equipments then
the a suitable liquid agent is added. Then the mixture is mixed thoroughly. In this
process  the  mixture  combines  with  the  liquid  agent  and  forms  small  spherical
structures. 
Excipients for pellets
Formulation  aids  or  excipients  are  added  to  pharmaceutical  dosage  forms
mainly to produce satisfactory delivery of the drug to the intended site,  to impart
favorable characteristic to the dosage form and to facilitate the manufacture of the
product. Since pellets are intended to be administered orally. The excipients used in
the pellet  dosage  forms are  typically  the  same as  those  used  in  tablet  or  capsule
formulations.  The  different  types  of  the  excipients,  disintegrants,  surfactants,  pH
adjusters, separating agents, spheronization enhancers, glidants and release modifiers
etc.. that are used in the development of the pellets are given in the following table.
Table 3: Examples of commonly used excipients.
Filler MCC, starch, sucrose, lactose, mannitol
Binder Gelatin, HPC, HPMC, MC, PVP, sucrose, starch,
Lubricant Calcium stearate, glycerin, PEG, Magnesium
stearate
Separating agent Kaolin, talc, silicon dioxide
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Disintegrant Alginates, cross carmellose sodium, MCC, avicel
pH adjuster Citrate, phosphate, meglumine.
Surfactant Polysorbate, SLS.
Spheronization
enhancer MCC, sodium CMC
Glidant Talc, starch, Magnesium stearate.
Release modifier Ethyl cellulose, carnauba wax, shellac.
Sugar spheres (Non pareil seeds, neutral pellets)
“Sugar spheres contain not more than 92% of sugar, calculated on dry basis.
The  remainder  consists  of  maize  starch.”  defined  according  to  European
pharmacopoeia.  Possibility to analyze the sugar spheres according to the Ph. Eur.,
USP/NF and JP. Produced accordance with the GMP. The sugar spheres are spherical
in structure these are in the manufacture of the pellets. These can be involved in the
development of the immediate release dosage forms or extended release dosage forms
or delayed release dosage forms. The drug suspension is prepared and is coated on the
sugar spheres to develop the immediate release dosage forms. The polymer coating
can be used to retard or extend the release of the drug from the pellets, this is used in
extended release dosage forms. In the delayed release dosage forms the pellets are
coated with an enteric coating to protect the acid labile drug.
 
Coating equipment
Most of the coating processes use one of the three general types of equipments.
1. The standard pan.
2. The perforated pan.
3. The fluidized bed coater.
1. Conventional pan system
The standard coating pan system consists  of a circular  metal  pan mounted
somewhat angularly on a stand, the pan is rotated on its horizontal axis by a motor,
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the hot air is directed into the pan and onto the bed surface, and is exhausted by means
of ducts positioned through the front of the pan. Coating solutions are applied by
spraying the material on the bed surface.
Figure 8: conventional coating pan.
2. The perforated coating pan
Neocota is an automatic coating system for tablets and pellets. Neocota is a
completely updated automatic coating system having a batch capacity of 500 gm to 1
kg. This model efficiently carries out the following operations: aqueous film coating
of tablets/pellets; Non-aqueous organic solvent based film coating of tablets/pellets;
and enteric film coating of tablets/pellets.
The basic system are has coating pan with perforations along its cylindrical
portion. It is driven by a variable speed drive with a flame-proof motor. Supply of hot
air and exhaust of drying air are arranged to facilitate the coating system through
stainless steel plenums positioned on both sides of the perforated coating pan. The pan
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is enclosed in a cylindrical airtight housing provided with a suitable door and front
glass  window.  This  housing  of  pan  with  drive  is  a  stainless  steel  cabinet
accommodating the gearbox, AC variable drive, power panel, hot air unit, exhaust unit
and an air fitter. Liquid spray system is complete with stainless steel liquid storage
vessel,  variable  flow-rate  liquid  dosing  pump,  automatic  spray  gun  and  inter-
connecting flexible hoses.
3. The fluidized bed coater
The fluid fed technology offers a very efficient coating technique. The major
advantage of the Fluid Bed Systems is that it is as per GMP standards and a closed
system. The second advantage of the Fluid Bed Systems is that not only coating but
granulation and pellet formation is also possible in the same machine.
Fluidized bed coating is a process that takes place inside a fluidized bed where by
a coat is introduced to cover the intended object in order to protect it or modify its
behavior. Particulate coating is a form of fluidized bed coating involving the coating
of solid particles inside the bed. In this process, a layer is deposited onto the surface
of fluidized solid particles by spraying with a solution of the coating material. The
fluidizing gas is also use to dry the deposited solution to form a coat on the surface of
the  particle.  There  is  considerable  diversity  in  methods  of  using  fluidized  bed
technology. For e.g. liquids can be applied to fluidized particles in a variety of ways,
including top, bottom and tangential spraying. For a given product, each method can
offer markedly different finished product characteristics. Fluidized beds are used for
coating because of their high energy and mass transfer. Fluidized beds for film coating
can be divided into three groups
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1. Top-spray.
2. Bottom-spray  equipment.
3. Tangential-spray.
1. Top spray
The expansion chamber is  lengthened to allow powder to remain fluidized
longer and to move with a higher velocity, so that agglomeration is minimized. The
expansion chamber is conically shaped to allow uniform deceleration of air stream.
The  filter  housing  is  larger  and  designed  to  shake  the  fines  back  into  the  bed
interrupting  fluidization;  this  reduces  agglomeration  tendencies.  The  nozzle  is
positioned low in the expansion chamber so that  coating material  impinge on the
fluidized particle a short distance from the nozzle; this reduces droplet spray drying
and provides for longer subsequent drying from the nozzle; this reduces droplet spray
drying and provides for longer subsequent dying of the coated particles. The top spray
coater  has  been  used  to  apply  aqueous  and  organic  solvent  based  film  coatings,
controlled release coatings.
2. Bottom spray coating (wurster process, 1953)
The  wurster  machine  employs  a  cylindrical  product  container  with  a
perforated plate. Inside the container is a second cylinder (coating partition) which is
slightly raised above the perforated plate, centered in the plate below this partition is a
spray nozzle used to dispense the coating solution. The perforated pate is designed
with  large  holes  in  the  area  under  the  coating  partition  and  smaller  holes  in  the
remainder of the plate, except for one ring of large holes at the perimeter. The design
allows  the  substrate  particles  to  be pneumatically transported  upward  through the
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coating  partition  and  downward  outside  this  partition.  Material  passing  through
coating partition receives a layer of coating material, dries in the expansion chamber
and falls back in a semi-fluidized state. Material circulates rapidly in this fashion and
receives a layer of coating material, dries in the expansion chamber and falls back in a
semi-fluidized state material circulated rapidly in this fashion and receives a layer of
coating on each pass through the coating partition.  The ring of large holes on the
periphery of perforated plate prevents the accumulation of material at the container
wall it has been used for coating small particles, pellets and tablets (wurster process,
1953).
Figure 9: Bottom spray coater
Table 4: Parameters used in bottom spray equipment
Inlet temperature 38-42°C
Product temperature 32-36°C
Exhaust temperature 32-38°C
Spray rate 8-12mg/min
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Peristaltic pump 12-18 rpm
Figure 10: Fluid bed processor pictorial representation (wurster process).
3. Tangential spray coating (Rotating disk granulator)
Granulation techniques utilizing centrifugal fluidizing drive have been studied
only  recently.  These  techniques  have  been  extended  to  coating  operations  and
combined with an expansion chamber to form the rotating disk granulator and coater
fluid bed device. The basic design a rotating disk in the product container.
The disk can be moved up or down to create a variable slit opening between
the outer perimeter of the disk and the sidewall of the container. Air is drawn into the
product container through the slit under negative pressure. This fluidizes the material
along the circumferential surface of the product container. At the same time the disk
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rotates at varying speeds and moves the product by the centrifugal force to the outer
portions where it is lifted by the fluidizing air steam into the expansion chamber. As
the material decelerates, it descends to the center of the disk and repeats the same
sequence. The fluidization pattern is often described as a spiraling helix or rope-like
pattern around the inside of the rotor chamber.
Spray nozzles can be immersed in the bed of fluidized material  and spray
applied in tangential fashion with respect to the particle flow.
Figure 11: Various fluid bed coating techniques.
                               Top spray               Bottom spray            Tangential spray
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2. REVIEW OF LITERATURE
Prasanth  et  al.,  (2011)  in  this  study  also  the  formulations  are  made  by
varying the concentrations of the polymers Hydroxy propyl methyl cellulose and ethyl
cellulose. In this the drug and polymer ratio used were 1:2. The polymers were also
used  in  varying  concentrations  to  each  other,  the  formulations  were  made  by
increasing  each  polymer  concentration  alternately.  In  the  formulation  with  more
concentration  of  ethyl  cellulose  showed  more  extended  drug  release  from  the
formulation.
Anand et al., (2011) this study was done to develop and optimize extended 
release formulation of Tamsulosin hydrochloride using the combinations of polymers 
lke ethyl cellulose and eudragit as coating material. In the preparation of the primary 
coating HPMC E-5 was used and SLS was used as the wetting agent. To optimize the 
formulation various evaluation tests were conducted like the uniformity of size, assay 
and the in-vitro dissolution tests. The optimized formulation was obtained by using 
eudragit at 9% and ethyl cellulose at 25% of the drug content.
Rama Rao Nadendla et al., (2011) the purpose of the present study was to
design, characterize and in vitro evaluation of sustained release pellets of metoprolol
succinate to reduce the dosing frequency employing pan coating technology. Initially
metoprolol  pellets  were  prepared  by  solution  layering  technology  over  non-pareil
seeds employing pan coating technology. Later, to sustain the release of drug over a
period 20 hrs, secondary coating was given over the drug layered pellets using ethyl
cellulose/  ethyl  cellulose-hydroxy  propyl  cellulose  were  used  to  prepare  different
formulations.  The prepared pellets were further  evaluated for surface texture,  flow
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properties and in vitro dissolution studies. Formulation F6 showed promising results
by sustaining the drug release up to 20 hrs. The in vitro dissolution studies revealed
that  the release  rate  is  inversely proportional  to percent  of  coating thickness.  The
mechanism of drug release follows Higuchi diffusion model.
N. N. Rajendran et al., (2011)  the present study was aimed to develop an
extended release  tablet  of  Metoprolol  Succinate for  the treatment of hypertension.
Four extended release formulations F1-F4 were developed using varying proportions
of Hydroxyl propyl methyl cellulose K100M, Sodium carboxy methyl cellulose and
Eudragit  L30  D55  by  wet  granulation.  Five  extended  release  formulations  F5-F9
containing HPMC K100M and HPMC 5cps in varying concentration were developed
by direct compression. The physico-chemical and in-vitro release characteristics of all
the formulations were investigated and compared. Two formulations, F7 and F8 have
shown not more 25% drug release in 1st h, 20-40% drug release at 4th h, 40-60% drug
release at 8th h and not less than 80% at 20th h and the release pattern conform with
USP specification for 24 h extended release formulation. It can be conclusively stated
that  optimum  concentration  of  HPMC  K100M  (58-65%)  by  direct  compression
method can yield an extended release of Metoprolol succinate for 24 hours. 
Parmar et al., (2011) the aim of the current study was to develop once-daily
sustained-release matrix tablets of metoprolol succinate, Selective β1- blocker used in
cardiovascular  diseases.  The tablets were prepared by the wet granulation method.
Ethanolic solutions of ethylcellulose (EC),  polyvinylpyrrolidone K30 were used as
granulating  agents  along  with  hydrophilic  matrix  polymer  hydroxypropyl
methylcellulose  (HPMC K100M).  The results  of  dissolution studies  indicated  that
batch AH3 (Drug-to-HPMC K100M, ethyl cellulose solution (4%W/V, as granulating
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agent) could extend the drug release up to 24 hours. Batch AH3 showed highest f2
value 84.95 and MDT 8.9 hrs similar to that of reference product. The dissolution data
were subjected to model fitting analysis and best fitted model was Higuchi model. All
the formulations (except batch AH3) exhibited diffusion-dominated drug release. The
mechanism of drug release from batch AH3 was diffusion coupled with erosion. 
Ajay L. et al., (2010) this work aims at investigating different types and levels
of hydrophilic matrixing agents, including sodium alginate (Alg), and Hydroxypropyl
methyl cellulose K15M (HPMC K15M) in an attempt to formulate controlled-release
matrix tablets containing 50 mg Metoprolol Succinate. The tablets were prepared by
wet  granulation.  The  Influence  of  three  granulating  fluid,  viz  acetone,  isopropyl
alcohol (IPA) & Dichloromethane (DCM) were also studied with a view to design &
develop slow release formulation of Metoprolol succinate. Prior to compression, the
prepared granules were evaluated for flow and compression characteristics. In vitro,
newly formulated controlled-release tablets were compared with standard commercial
tablets (Met®XL50). The excipients used in this study did not alter physicochemical
properties of the drug, as tested by FTIR. The prepared matrix tablets showed good
mechanical properties (hardness and friability). Hydroxypropyl methyl cellulose and
Alginate-based tablet formulations showed high release retarding efficiency, and good
reproducibility.  FTIR  study  suggesting  that  HPMC K15M and Alginate  are  good
candidates for preparing modified release tablet formulations Metoprolol succinate. 
B. Yilmaz (2010) in this study, zero-, first-, second- and third-order derivative
methods  were  developed  for  the  determination  of  metoprolol  in  pharmaceutical
preparations. In zero order spectrophotometry,  absorbance values were measured at
276 nm in zero order spectra of solution of metoprolol in methanol in the range of
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240-310 nm. In first derivative spectrophotometry, absorbance values were measured
at 265, 278 and 285 nm. In second derivative spectrophotometry, absorbance values
were measured at 276, 279, 287 and 282 nm. In third derivative spectrophotometry,
absorbance  values  were  measured  at  275,  278  and  281  nm.  Parameters  such  as
linearity,  precision,  accuracy,  specificity,  stability,  limit  of  detection  and  limit  of
quantization  were  studied  according  to  the  International  Conference  on
Harmonization Guidelines. All the methods developed were successfully applied to
two tablet formulation and the results were compared statistically with each other. 
Gummudavelly et  al.,  (2010)  formulate  and  characterize  extended  release
matrix  tablets  of  metoprolol  succinate  using  hydrophilic  polymers  like  Hydroxy
Propyl Methyl Cellulose (HPMC K100M), Hydroxy Propyl Cellulose (HPC), Ethyl
Cellulose, Carbopol 934 and Megnesium Stearate, and these selected matrices were
directly compressed into tablet. Release kinetics evaluated by using USP-22 (Paddle)
dissolution  apparatus.  In-vitro release  study  showed  that  ERT10  for  25mg  label
claimed were well suited to extend release for 20 hours with zero order release.
Bhupendra et  al.,  (2010)  this  study was  conducted  to  develop once  daily
tablet  of  Nicorandil  for  the  treatment  of  angina.  In  this  study both  the  polymers
HPMC  (hydrophilic)  and  ethyl  cellulose  (hydrophobic)  were  used  in  different
proportions  to  develop  the  extended  release  tablet.  When  the  formulation  was
incorporated with HPMC and Ethyl cellulose in 1:2 ratio is showed the sustained drug
release for about 22hrs and the drug release was found to be 91%. 
Manna  niranjan  kumar et  al,  (2010)   mucoadhesive  microcapsules  of
metoprolol succinate ,a β1‐adrenergic blocker and antihypertensive agent , have been
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prepared  from  sodium  alginate  ,hydroxyl  propyl  methyl  cellulose‐
K4M&E5LV,carbopol 934P, sodium CMC using 10% w/v calcium chloride solution
by  ionic  gelation  method.  Drug  :  polymer  ratio  was  1:1  in  all  formulations  and
polymer  mixtures  employed  were  1:1,2:1,3:1,4:1  of  sodium  alginate:
polymer(hydroxyl  propyl  methyl  cellulose‐K4M&E5LV,  carbopol  934P,  sodium
CMC).Calcium  chloride  was  used  for  ionic  gelatin  and  cross  linking  of  sodium
alginate molecules. Microcapsules were spherical in shape and of sizes between 585
microns to 845 microns . Carbopol 934P was found most effective in controlling drug
release from microcapsules followed by hydroxyl propyl methyl cellulose K4M. Drug
release from the best formulation from carbopol 934P follows Higuchi model while
that from hydroxyl propyl methyl cellulose K4M follows anomalous transport.
Antesh K Jha et al., (2009) the objective of the present study was to develop
sustained-release  matrix  tablets  of  metoprolol  succinate,  β1-selective  adrenergic
receptor blocking agent. The tablets were prepared by the wet granulation method.
Ethanolic  solutions  of  ethylcellulose  (EC)  and  polyvinylpyrrolidone  were  used  as
granulating  agents  along  with  hydrophilic  matrix  materials  like  hydroxy  propyl
methylcellulose (HPMC) and guar gum. The granules were evaluated for angle of
repose,  bulk  density,  compressibility  index,  total  porosity,  and  drug  content.  The
tablets were subjected to weight variation test, drug content, hardness, friability, and
in  vitro  release  studies.  The  granules  showed  satisfactory  flow  properties,
compressibility,  and  drug  content.  All  the  tablet  formulations  showed  acceptable
pharmacotechnical  properties.  The  results  of  dissolution  studies  indicated  that
formulation F1 (drug-to-HPMC, 1:4; ethanol as granulating agent) could extend the
drug release up to 12 hours. In the further formulation development process, F5 (drug-
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to-HPMC, 1:4; EC 4% wt/vol as granulating agent), the most successful formulation
of  the  study,  exhibited  satisfactory  drug  release.  All  the  formulations  exhibited
diffusion-dominated drug release. 
Deshmukh  et  al., (2009) design  and evaluate  oral  sustained  drug delivery
system for Metoprolol Succinate using natural hydrophilic gums such as karaya gum
and xanthan gum as a release modifier. Nine batches were prepared by using karaya
gum (KG) and xanthan gum (XG) in concentration of 15%, 20% and 25% alone and
in combination of 2:8. Matrix tablets were prepared by wet granulation method and
were  evaluated.  Among  the  formulations  studied,  formulation  F8  containing
combination of  KG and  XG (2:8)  having concentration of  20% showed sustained
release  of  drug  for  12hrs  with  cumulative  percent  release  of  99.24%.  The matrix
formulation F8 showed sustained release of Metoprolol  Succinate by the diffusion
mechanism.
Gohel  et  al.,  (2009)  to  fabricate  modified  release  tablet  of  Metoprolol
Succinate  using  hydroxy  propyl  methylcellulose  (HPMC)  and  xanthan  gum  as  a
matrixing  agent.  A 32 full  factorial  design  was  employed  for  the  optimization  of
formulation. The percentage drug released at a given time (Y60, Y240 and Y720) and the
time required for a given percentage of drug to be released (t50%) were selected as
dependent variables. The  in-vitro drug dissolution study was carried out in PH 6.8
phosphate buffer employing paddle rotated at 50 rpm.
Moreshwar N.Kulkarni et al., (2009) validated Spectrophotometric method
for the estimation of Metoprolol in bulk drug has been developed. In method Distilled
water,  0.1NHcl,  Phosphate  Buffer6.8  were  used  as  solvent  and  shows  absorption
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maximum at 224 nm. The Beer’s law range for Distilled water, Phosphate buffer was
in 5-30 µg/ml and 10-50 µg/ml for 0.1 NHCL. The method was found to be linear,
accurate and precise.
Reeta  et al., (2009) To reduce the frequency of dose administration and to
prevent nocturnal heart attack and to improve the patient compliance by developing
extended  release  (ER) matrix  tablet  of  Metoprolol  succinate.  Eight  batches  of  ER
matrix  tablets  of  Metoprolol  succinate  were  developed  by  using  wet  granulation
technique and coated with hydroxy propyl methyl cellulose (KM 100) and hydroxyl
methyl  cellulose  for  extended  release.  Among  the  eight  formulations,  F8  showed
extended  release  of  drug  for  20  hours  with  87.1% drug  release  and  subjected  to
stability studies for 3 months at 40°C/75% RH and 60°C/80%RH.
William et al., (2009) studied the effects of Metoprolol Succinate extended
release vs. Amlodipine Besilate on the blood pressure, heart rate, and the rate-pressure
product  in  patients  with  hypertension.  The  results  of  the  study demonstrated  that
Metoprolol Succinate ER induced greater reductions in early morning BP, HR, and
FPP than Amlodipine in middle-aged patients with Stages 1 and 2 hypertension.
Nisarur-ur-Rahman et  al.,  (2008) reported  an  In  vivo  performance  of
controlled release pellets of diltiazem HCl   was evaluated in vivo, in comparison with
Herbesser SR. six healthy volunteers perspired in the study, conducted according to
randomized, two-way parameters   plasma concentration-time curve, C Max T Max  were
estimated  from  the  plasma  concentration  –time  profile  for  each  volunteers.  The
formulations started to release their drug content immediately upon rupture of the
capsules but in sustained manner
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SH Lakade & MR Bhalekar, (2008) the objective of the present study was to
develop  hydrophilic  polymer  (HPMC) and  hydrophobic  polymer  (Ethyl  cellulose)
based Nicorandil matrix sustained release tablet which can release the drug up to time
of  24 hrs  in  predetermined  rate.  The formulation of  Nicorandil  matrix  tablet  was
prepared  by  the  polymer  combination  in  order  to  get  required  theoretical  release
profile.  The  influence  of  hydrophilic  and  hydrophobic  polymer  and  granulation
technique on Nicorandil was studied. The formulated tablet were also characterized
by physical  and  chemical  parameters,  The  in-vitro  release  rate  profile  should the
higher  concentration of  F2 polymer  in  tablet,  the combination of  hydrophilic  and
hydrophobic combination showed less result than use of alone. The in–vitro release
data was well fit to Peppas and Hixon crowel release kinetics. 
K. Kannan et al.,  (2007) dissolution test  for sustained release capsules of
Metoprolol  125  mg  was  developed  and  validated  according  to  FDA  and  ICH
guidelines.  Metoprolol  coated  pellets  were  coated  with  microcrystalline  wax  and
glyceryl distearate for slow release of drug. The dissolution method which uses USP
apparatus I (Basket) with rotating at 100 rpm, 900 ml of different dissolution medium,
ultra  violet  spectroscopy  for  quantification  was  demonstrated  to  be  robust,
discriminating and transferable. Dissolution tests conditions were selected after it was
demonstrated that the Metoprolol rapidly dissolved in the aqueous media over the pH
range of 1.2 to 7.4. 
Hainer  et  al., (2007)  lowering  elevated  blood  pressure  (BP)  with  drug
therapy reduces the risk for catastrophic fatal and nonfatal cardiovascular events such
as stroke and myocardial  infarction.  Given the heterogeneity of  hypertension  as a
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disease,  the  marked  variability  in  an  individual  patient’s  BP  response,  and  low
response rates with monotherapy, expert groups such as the Joint National Committee
(JNC) emphasize  the  value  of  combination antihypertensive  regimens,  noting  that
combinations,  usually  of  different  classes,  have  additive  antihypertensive  effects.
Metoprolol  Succinate  extended-release  tablet  is  a  beta-1  (cardio-selective)
adrenoceptor-blocking agent formulated to provide controlled and predictable release
of metoprolol.
A.Hamid et  al., (2006) formulated and Evaluated of Once-Daily tablets of
Cefpodoxime using hydroxypropyl methylcellulose. Tablets were prepared by direct
compression.  In  vitro  drug  release  was  evaluated  using USP Apparatus-II.  It  was
found that 16.86% of the drug was released during the first hour. During the initial 9
hours,  ~50%  of  the  drug  was  released.  After  9  hours,  the  release  rate  increased
slightly, until the 21st hour, and then release slowed but continued until the 24-hour
mark.  Hence,  the formulation can  be  considered  as  a  once-daily sustained-release
tablet of Cefpodoxime Proxetil.
M. Harris shoaib et al.,  (2006) have been developed once-daily sustained
release matrix tablet of ibuprofen using hydroxypropyl  methylcellulose (HPMC) as
release  controlling  factor  and  to  evaluate  drug  release  parameters  as  per  various
release kinetic models. In order to achieve required sustained release profile tablets
were  directly  compressed  using  Avicel  pH  101  and  Magnesium  stearate.  The
formulated tablets were also characterized by physical and chemical parameters and
results were found in acceptable limits. Different dissolution models were applied to
drug release data in order to evaluate release mechanisms and kinetics. Criteria for
selecting  the  most  appropriate  model  was  based  on  linearity  (coefficient  of
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correlation). The drug release data fit well to the Higuchi expression. Drug release
mechanism was found as a complex mixture of diffusion, swelling and erosion.
Sandip et al., (2003) this studied was designed to formulate the controlled release
formulation  of  the  Tramadol  hydrochloride  by  using  the  different  proportions  of  the
hydrophilic and hydrophobic polymers. The hydrophilic polymer used was HPMC and the
hydrophobic polymer used was ethyl cellulose. The results reported that increase in ethyl
cellulose concentration retarded the drug release from the dosage form.
Claudio  et  al., (2000) the  goal  of  the  present  study  was  to  evaluate  the
influence of the formulation and operating conditions on pellets preparation by pan
technique  application  of  powdered  drug  on  sugar  based  cores  .inert  cores  were
intermittently  treated  with  micronized  drug  powder  and  adhesive  solution  .drug
layering by GS automated pan coating system. Core resulting in the production of
pellets  that  can  further  coated  by  different  polymers  to  obtain  modified  release
formulations different  procedures have been used to evaluate a series of important
parameters such as initial cores weight. Speed of powder application, speed type and
position  of  the  atomizers,  atomization  degree,  temperature  and  air  spray.  At  first
covered with seal coating then followed by enteric coating.
Michael r. bristow, (2000) in this article the detailed description of the angina
pectoris and other related diseases were described briefly. This article also includes 
the drugs which are used mostly in the treatment of the angina pectoris. This deals 
mainly with the β-adrenergic receptor blockade in chronic heart failure. A detailed 
description of the use of the drug Metoprolol was also studied in this article.
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Paul  et  al.,  (1992) sustained-release  tablet  matrix  systems  containing
hydroxypropyl  methylcellulose  to  physically  withstand  the  mechanical  processes
involved in a reworking procedure. The authors also studied the influence of polymer
chemistry (substitution),  the  rework  procedure,  powder  reblending  levels,  and  the
compression force on particle-size distribution, tablet friability,  and tablet hardness
characteristics.  Also  investigated  were  the  impact  of  the  milling,  remixing,  and
recompression processes  on the  in vitro drug release  dissolution profiles  for  three
model drugs, ascorbic acid, chlorpheniramine maleate, and meclizine dihydrochloride.
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3. AIM AND PLAN OF WORK
Aim
The aim and of the present study is to develop a pharmaceutically stable and
quality improved formulation of  Metoprolol  succinate extended release pellets.  To
achieve  this  goal  various  prototype  formulation  trials  were  formulated  and  the
evaluated with respect to the various quality controls such as dissolution, assay and
stability studies will be under taken.
The  primary  objective  of  this  study  is  to  prepare  drug  loaded  pellets  of
metoprolol succinate (MS) using solution layering technology, and to give functional
coating of pellets with ethyl cellulose (EC), in the present study EC is used due to its
convenient film formability, good physicochemical properties and minimum toxicity.
HPMC confers the film a more hydrophilic nature and alters its structure by virtue of
pores and channels through which the substance can diffuse more easily to control the
release properties of drug formulation. The coating parameters like batch size, pan
rpm, spray pattern and temperature of the bed were optimized in order to get efficient
drug  loading  and  uniform functional  coating.  Metoprolol  succinate  is  used  in  the
treatment  of  hypertension,  chest  pain  (angina  pectoris)  and  myocardial  infraction
either alone or in combination with other drugs.
Pellets are of great interest to the pharmaceutical industry for various reasons.
Pelletized product not only offers flexibility in dosage form design and development,
but also utilized to improve safety and efficacy of bioactive agent. A multiunit pellet
system (MUPS) is an approach to develop capsule formulation, capsule containing
MUPS,  when  administered  drug  dispersed  in  it.  Each  pellet  acts  a  single  unit.
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Consequently  as  a  separate  drug  delivery system.  The MUPS have god  desirable
distribution  characteristics,  reproducibility,  transit  time  and  reduce  chance  of
localization of drug delivery.  It  is having less prone to adherence to the intestinal
walls, naso-gastric and gastromy tubes and giving predictable delivery of the product
to the site of drug release.
Plan of Work
 Literature collection.
 Selection of drug and excipients.
 Pre-formulation studies.
 Compatibility studies.
 Formulation and evaluation of core pellets.
 Formulation and evaluation of coated pellets
 Evaluation of pellets loaded in capsules.
 Stability studies.
 Kinetic studies.
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4. MATERIALS AND METHODS
4.1 List of materials 
The materials which are used in this formulation and evaluation are illustrated 
in the following table.
Table 5: List of the materials used in the formulation 
S.No. Material Manufacture
1 Metoprolol succinate Hetero drugs limited,Hyderabad.
2 Mannitol signet chemicals,
mumbai
3 HPMC Aurolab, Mudhurai.
4 Isopropyl alcohol FMC biopolymer
5 Ethyl cellulose M50 FMC biopolymer
6 Sodiumlauryl sulphate Ranq. RemediesPvt.Ltd
7 Iron oxide Colorcon Asia PvtLtd.
4.2 List of equipments
The equipments which are used in the formulation and evaluation are 
illustrated below in the following table.
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Table 6: List of equipments used in the formulation 
4.3
Drug profile
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S.No. Equipment Manufacturer
1 Electronic balance. Sartorius LA120S
2 Sieves. Retsec ASL00
3 Tapped density meter. Electrolab ETD-1020
4 Conventional coating pan or
spray gun. Rinak, kalweka HD410AC
5 Fluidized bed coater. Row land chem. Machinespvt ltd.
6 Hardness tester. Pharmatest PTB-311E
8 Dissolution test apparatus. Elecctro lab USP XXII
9 Homogenizer. Chamunda pharma
machinery pvt. Ltd.
10 Fluidized bed dryer. Rowland chem. Machinespvt. Ltd.
11 Peristaltic pump. Enertech electronics pvt. Ltd.
12 Disintegration tester Electro lab ED-2L
13 Overhead stirrer. Remi motors Bombay RQG-129D
14 Moisture balance or LOD
apparatus. Sartorious
15 Vernier calipers. Mitulya absolute
16 Capsule filling machine. Palm CFM 2005
17 Stability chambers Thermo lab standard
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Metoprolol succinate 
Metoprolol succinate is used for a number of conditions like hypertension, 
angina pectoris, acute myocardial infarction, supra-ventricular tachycardia, ventricular
tachycardia, congestive heart failure and prevention of migraine headaches. Due to its 
selectivity in blocking the β1 receptors in the heart, metoprolol is also prescribed for 
off-label use in performance anxiety, social anxiety disorder and other anxiety 
disorders.
Metoprolol is a selective β1 receptor blocker used in treatment of several 
diseases of the cardiovascular system, especially hypertension. The active substance 
metoprolol is employed either as metoprolol succinate or metoprolol tartarate (where 
100 mg metoprolol tartarate corresponds to 95 mg of metoprolol succinate). The 
tartarate form is an immediate-release and the succinate form is an extended- release 
formulation ( k.kannan et al, 2007).
Figure 12: Structure of Metoprolol succinate
Empirical formula : [(C15H25NO3)2.C4H6O4]  
IUPAC name :±1-(isopropylamino)-3-[p-(2-
                                      methoxyethyl)phenoxy] -2-propanal 
succinate
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Table 7: Physico-chemical properties of Metoprolol succinate
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Parameter Characteristic
Description White crystalline powder
Chemical name
±1-(isopropylamino)-3-[p-(2-
methoxyethyl)phenoxy]-2-propanal succinate
Molecular formula C19H30NO7
Molecular weight 652.8
Solubility
Freely soluble in water.
Soluble in methanol.
Sparingly soluble in ethanol.
Slightly soluble in dichloromethane and 2-
propanol.
Insoluble in ethyl-acetate, acetone, diethyl ether
and heptane.
Functional category
In the treatment for hypertension angina pectoris
and heart failure.
Pharmacopoeial status
British pharmacopoeia (BP), European
pharmacopoeia (EP) and United states of
America pharmacopoeia (USP).
Storage conditions
Store at room temperature (25°C /77°F) away
from light and moisture. Do not store in wet
places.
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Site and mode of action
The β-adrenergic blocking agents decrease the oxygen demands of the 
myocardium by lowering both the rate and the force of contraction of the heart. They 
suppress the activation of the heart by blocking β-1 receptors, and they reduce the 
work of the heart by decreasing cardiac output and blood pressure. The demand for 
oxygen by the myocardium is reduced both during exertion and at rest. 
The mechanism of action of the antihypertensive effects of beta-blocking 
agents has not been elucidated. However, several possible mechanisms have been 
proposed: 
1) Competitive antagonism of catecholamines at adrenergic neuron sites (especially 
cardiac), leading to decreased cardiac output. 
2) A central effect leading to reduced sympathetic outflow to the periphery.
3) Suppression of rennin activity.
Pharmacokinetics 
Absorption and Distribution
The drug is absorbed rapidly from the intestine and it is completely absorbed. 
Plasma levels following oral administration of conventional metoprolol tablets 
approximate 50% of levels and crosses the blood-brain-barrier and has been reported 
in the CSF in a concentration of 78% of the simultaneous plasma concentration. The 
drug is also rapidly metabolized extensively in the liver. Plasma levels achieved are 
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highly variable after oral administration. Only a fraction of the drug (about 12%) is 
bound to human serum albumin.
Metabolism and Excretion
Metoprolol undergoes α-hydroxylation, O-demethylation and N-dealkylation 
as a substrate of the cytochrome liver enzymes CYP2D6 and a small percentage by 
CYP3A4. Metoprolol is a racemic micture of R and S en-antiomers and is primarily 
metabolized by CYP2D6. When administered orally, it exhibits stereo-selective 
metabolism. Elimination undergoes mainly by biotransformation in the liver, and the 
plasma half-life ranges from approximately 3 hrs to 7 hrs and less than 5% of an oral 
dose of metoprolol is excreted unchanged in urine, the rest is excreted by the kidneys 
as metabolites. The metabolites do not have any beta-blocking activity.
When metoprolol is administered intravenously, the unchanged drug excreted 
through urine is approximately 10%. The systemic availability and half-life of 
metoprolol in patients with renal failure do not differ to a clinically significant degree 
from those in normal subjects. Therefore no reduction in metoprolol succinate dosage 
is usually advised in patients with chronic renal failure.
Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is 
absent in about 8% in Caucasians (poor metabolizers) and about 2% of most other 
populations. CYP2D6 can be inhibited by a number of drugs. Poor metabolizers and 
extensive metabolisers who use CYP2D6 inhibiting drugs will have increased 
metoprolol blood levels and thus decreasing metoprolol’s cardio-selectivity.
Department of pharmaceutics                      49         JKKMMRF college of 
pharmacy
Chapter 4                                                                                    Materials and
methods
The bioavailability of metoprolol shows a dose-related, although not directly 
proportional, increase with dose and is not significantly affected by food following 
Metoprolol succinate administration.
Table 8: Pharmacokinetics and Pharmacodynamics of Metoprolol succinate
Parameters Data
Tmax (hrs)
(R)-Metoprolol
(S)-Metoprolol
1.0±0.3 (hr)
1.0± 0.3
1.0± 0.3
Auc (ng.h/ml)
(R)-Metoprolol
(S)-Metoprolol
(S)/(R) AUC ratio
169± 155
279± 237
1.72± 0.27
Bioavailabilty 12%
Cmax (ng/ml)
(R)-Metoprolol
(S)-Metoprolol
52± 49 = 0.52±0.49 mcg/ml
76± 57 = 0.76±0.57 mcg/ml
Biological half life 3-7hrs
Site and mechanism of
absorption GIT.
Serum protein binding
Small portion of the drug (12%)
is bound to serum albumin.
Route of metabolism Hepatic via CYP2D6, CYP3A4
Metabolites
Alpha-hydroxy-metoprolol and
O-demethylmetoprolol.
Activity of metabolites
Alpha-hydroxy-metoprolol has β
blockade action.
Route of excretion Renal
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Route of administration Oral
Indications
Angina pectoris, hypertension
and myocardial infarction.
Pediatrics
The pharmacokinetic profile of Metoprolol succinate was studied in 120 
pediatric hypertensive patients (6-17 yrs of age) receiving dose ranging from 12.5 to 
200mg once daily. Age, gender, race and ideal body weight had no significant effects 
on metoprolol pharmacokinetics. Metoprolol apparent oral clearance (CL/F) increased
linearly with body weight. Metoprolol pharmacokinetics have not been investigated in
patients < 6yrs of age.
Adverse Effects
Central Nervous System 
The Metoprolol succinate affects the central nervous system. Tiredness and 
dizziness have occurred in about 10 of 100 patients. Depression has been reported in 
about 5 of 100 patients.  Mental confusion and short-term memory loss have been 
reported.  Headache, somnolence, nightmares, and insomnia have also been reported
Cardiovascular system
The Metoprolol succinate affects the central nervous system. Shortness of 
breath and bradycardia has occurred in approximately 3 of 100 patients. Cold 
extremities, arterial insufficiency, usually of the Raynaud type, palpitations, 
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congestive heart failure, peripheral edema, syncope, chest pain, and hypotension have 
been reported in about 1 of 100 patients.
Gastrointestinal
Metoprolol succinate also effects the the gastro intestinal tract in higher doses. 
Diarrhea has occurred in about 5 of 100 patients. Nausea, dry mouth, gastric pain, 
constipation, flatulence, digestive tract disorders, and heartburn have been reported in 
about 1 of 100 patients.
Dosage and Administration
The drug should be taken as prescribed by the physician. The drug is available
in the form of immediate and extended release tablet intended for either multiple 
doses per day or once-a-day administration.
Contraindication
Metoprolol generally is contraindicated for the treatment of acute myocardial 
infarction in patients with heart rates of less than 45 beats per minute, heart block 
greater than first-degree (PR interval ≥0.24 second), systolic blood pressure <100 mm
Hg, or moderate-to-severe heart failure.
Drug interactions
Catecholeamine depleting drugs
Catecholeamine-depleting drugs (eg, reserpine, monoamine oxidase (MAO) 
inhibitors) may have an additive effect when given with beta-blocking agents. Obese 
patients treated with Metoprolol succinate plus a catecholeamine depletor for 
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evidence of hypotension or marked bradycardia, which may produce vertigo, syncope,
or postural hypertension.
CYP2D6 inhibitors
Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine and 
propafenone are likely to increase metoprolol concentration. In healthy subjects with 
CYP2D6 extensive metaboliser phenotype 200 mg tripled the concentration of S-
metoprolol and doubled the metoprolol elimination half-life. In four patients with 
cardiovascular disease, co-administration of propafenone 150 mg t.i.d with immediate
release metoprolol 50 mg t.i.d resulted in two to five fold increases in the steady-state 
concentration of metoprolol. These increases in plasma concentration would decrease 
the cardio-selectivity of metoprolol.
Digitalis, Clonidine and Calcium channel Blockers
Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular 
conduction and decrease heart rate. Concomitant ude with beta clockers can increase 
the risk of bradycardia.  If clonidine and a beta blocker, such as metoprolol are co-
administered, withdraw the beta-blocker several days before the gradual withdrawal 
of clonidine because beta-blockers may exacerbate the rebound hypertension that can 
follow the withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, 
delay the introduction of beta-blockers for several days after clonidine administration 
has stopped.
Hypertension and Angina Cardiac Failure
Sympathetic stimulation is a vital component supporting circulatory function 
in congestive heart failure, and beta-blockade carries the potential hazard of further 
Department of pharmaceutics                      53         JKKMMRF college of 
pharmacy
Chapter 4                                                                                    Materials and
methods
depressing myocardial contractility and precipitating more severe failure. In 
hypertensive and angina patients who have congestive heart failure controlled by 
digitalis and diuretics, extended release metoprolol succinate should be administered 
cautiously. Both digitalis and extended release metoprolol succinate slow AV 
conduction.
Excipients profile
Sugar spheres
Table 9: Characteristics of sugar spheres
Synonyms
Non pareil, NPTAB, Nu-Core, Nupareil, sugar seeds
and suglets.
Description
These are approximately spherical granules of a
labeled nominal size range with a uniform diameter.
Functional categories Tablet and capsule diluents.
Stability and storage
conditions
Sugar spheres are stable when stored in a well-closed
container in a cool dry place.
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Method of manufacture
Sugar spheres are prepared from crystalline sucrose,
which is cored using sugar syrup and a starch dusting
powder.
Applications
Sugar spheres are mainly multi-particulate sustained
release formulations. Complex drug mixture
contained in a single dosage form can be prepared by
coating the drugs onto different batches of sugar
spheres with different protective polymer solutions.
 Mannitol
Table 10: Characteristics of Mannitol
Synonyms
Mannite, Pearlitol, manna sugar and cordycepic
acid.
Empirical formula C6H14O6
Description
Mannitol occurs as white, odorless, crystalline
powder or free flowing granules and sweet in taste.
Functional category
Sweetening agent and tablet and capsule diluent,
and tonicity agent.
Solubility
Solvent at 20°C
Solution                 Solublity
Ethanol                   1 in 8
                   Ether                   practically insoluble
Water                      1 in5.5
Loss on drying 0.3%
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Melting point 166-168°C
Stability and storage
conditions
Stable in dry state and in aqueous solution. Should
be stored in a well closed container, in a cool and
dry place.
Incompatibilities
Precipitation has been reported to occur between
25%w/v mannitol solution with plastic.
Applications
It is used as a Diluent also suggested as plasticizer
in a soft gelatin capsule, granulation containing
agent, mannitol have the advantage of being dried
easily.
Hydroxy Propyl Methyl Cellulose 
Table 11: Characteristics of Hydroxy Propyl Methyl Cellulose (HPMC)
Synonyms Methocel and hypromellose.
Description White or similar white fibrous or grain powders, no
odor was observed.
Functional categories
Densifiers, dispersing agent, emulsifying agent,
lubricator and film former used as rheology modifier
as well as water retaining agent for film formation,
synthetics adhesives as well as tablet coating,
controlling polymer, Stabilizing agent, binder and
viscosity enhancer
Solubility
Slightly insoluble in ethanol without water, diethyl
ether, acetone, it swells in cold water and forms a
clear or tiny turbid colloid solution.
Loss on drying ≤5%.
Stability and storage
conditions
It is chemically and physically stable at ambient
temperature for at least 3–4 years and for 2–3
months at 40°C and 75% relative humidity. It is
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stable on exposure to UV light for up to 3 months at
25°C and 70% relative humidity. In general,
hypromellose phthalate is more stable than cellulose
acetate phthalate. At ambient storage conditions
hypromellose phthalate is not susceptible to
microbial attack.
Melting point Brown at 190 - 200°C and then char at 225 - 230°C.
Incompatibilities Incompatible with strong oxidizing agents.
Applications
It can be used as densifiers , dispersing agent,
emulsifying agent, lubricator and film former etc. It
can be used in food and in cosmetics, and daily
chemical industries too
Isopropyl alcohol 
Table 12: Characteristics Isopropyl alcohol 
Synonyms
Isopropanol, propan-2-ol, 2-propanol or the
abbreviation IPA, propan-2-ol, diethyl cardinal,
isopropanol, petrohol, 2-propanol.
Empirical formula C3H8O
Description
It is a clear colorless, mobile, volatile, flammable
liquid with a characteristic spirituous odour
resembling that of a mixture of ethanol and
acetone, it has a slight bitter taste.
Functional categories Solvent, disinfectant.
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Solubility
miscible in water, benzene, chloroform, ethanol,
ether and glycerin soluble in acetone and
insoluble in salt solutions.
Moisture content 0.1-13%w/w commercial grades 13%w/w.
Melting point −89 °C
Stability and storage
conditions
Store in well-closed container in a cool  and dry
place.
Applications
Solvent for coatings or for industrial processes.
Isopropyl alcohol in particular is popular for
pharmaceutical applications
Ethyl cellulose 
Table 13: Characteristics of Ethyl cellulose 
Synonyms Acquacoat ECD, Aqualon E462, Ethocel andSurelease
Empirical formula C12H23O6 (C12H22O5) n C12H23O5
Description
The main use of ethyl cellulose in oral formulations
is as a hydrophobic coating agent for tablets and
granules. Ethyl cellulose coatings are used to
modify the release of a drug, to mask an unpleasant
taste, or to improve the stability of a formulation. It
is tasteless, free flowing, white to tan colored
powder.
Functional categories
Plasticizer, solvent, tablet and capsule lubricant,
coating agent, flavoring agent, fixative, tablet
binder filler and viscosity increase agent.
Solubility Dispersible in water and soluble in Ethers, freely
soluble in chloroform methyl acetate. Insoluble in
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glycerin.
pH 3 – 11
Loss on drying < 3%
Melting point 129–133°C
Density 0.4 g/cm3
Stability and storage
conditions
Chemically stable, stored in well-closed container
in a cool and dry place. Slightly absorbs moisture
(hygroscopic). Resists the alkalis, salt solutions
acidic materials more sensitive.
Applications
Use                                            Concentration (%)
Micro encapsulation                                  10.0–20.0
Sustained-release tablet coating                 3.0–20.0
Tablet coating                                             1.0–3.0
Tablet granulation                                       1.0–3.0
Yellow oxide
Table 14: Characteristics of Yellow oxide
 
Synonyms Iron oxide, red oxide and ferric oxide hydrate.
Empirical formula Fe2O3·H2O
Description
Solid material color ranges from yellow through
dark-brown to black. It is also used in aquarium
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water treatment as a phosphate binder.
Functional categories Pigment, coloring agent.
Solubility In-Soluble in water.
Melting point 1565°C
Stability and storage
conditions
Store in a clean, dry area at ambient temperature
in original unopened containers. Conditions of
high humidity may require storage in a
controlled environment.
Incompatibilities
Not compatible with hydrazine, calcium
hypochlorite, per-formic acid and bromine
pentafluoride.
Applications
It is used in cosmetics, tattoos and as coloring
agent in pharmaceutical industry.
Sodium lauryl sulphate (SLS)
Table 15: Characteristics of Sodium lauryl sulphate (SLS)
Synonyms
Sodium dodecyl sulfate (SDS or NaDS), Sodium
monododecyl sulfate, Sodium lauryl sulfate,
Sodium monolauryl sulfate, Sodium
dodecanesulfate, dodecyl alcohol, hydrogen
sulfate, sodium salt, n-dodecyl sulfate sodium
and Sulfuric acid monododecyl ester sodium salt.
Empirical formula CH3(CH2)11OSO3Na
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Description White crystalline flakes
Functional categories
Surfactants, Surface-active agents, wetting
agents, foaming agents, dispersing agents and
emulsifying agents.
Solubility In-Soluble in water
Loss on drying 5%
Melting point 206°C
Stability and storage
conditions Store at room temperature, Keep away from light
Incompatibilities
Incompatible with strong oxidizers, cationic
materials and with acids pH less than 2.5.
Applications
It is used as a disintegrant due to its surfactant
and wetting properties, removal of oily stains and
residues. It is used in toothpastes, shampoos,
shaving foams and bubble bath formulations in
part for its thickening effect and its ability to
create lather. It is also used in lysing cells during
DNA extraction.
4.3  Pre-formulation studies 
Pre-formulation testing was an investigation of physical and chemical 
properties of a drug substance alone and when combined with excipients. It is the first
step in the rational development of dosage forms.
Objective of pre-formulation study
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Pre-formulation studies on active pharmaceutical ingredients (API), inactive 
ingredients (Excipients), and their combinations were carried out to meet the 
following purposes
1.  To finalize specifications of active pharmaceutical ingredients (API).
2. To study the compatibility between active and inactive ingredient.
3. Characterization of reference product.
For any drug substance to formulate into a dosage form, it is necessary to 
study the physicochemical properties of the bulk drug like physical appearance, 
solubility, bulk density, tapped density, compressibility, melting point, molecular 
weight, sieve analysis
Scope
The use of pre-formulation parameters in the manufacturing of the 
pharmaceutical dosage forms maximizes the chances in formulating an acceptable, 
safe, efficacious and stable product.
The pre-formulation study can be divided into two sub-classes
1. API characterization. 
2. Compatibility study.
 Active pharmaceutical ingredient (API) characterization
Organoleptic evaluation
These are preliminary characteristics of any substance before going for the 
manufacturing process of the dosage forms. These studies are useful in identification 
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of specific material by comparing their characters with the required characters. 
Following physical properties of API were studied.
a. Color
b. Odor
c. Taste
Solubility analysis
The solubility analysis is done for the drug. These analysis are done to know 
the solubility characters of the drug and to select the best vehicle or diluent in which 
the drug can be dissolved or suspended to form the best pharmaceutical dosage form. 
The solubility characters of the present drug are done and the results are given in the 
following table.
Physical characteristics
 Loss on drying
This is specified in EP, BP and USP. Although the loss in weight, in the 
samples so tested, principally is due to water, small amount of other volatile materials 
will a contribute to the weight loss. The moisture balance combines both the drying 
process and weight recording, it is suitable where large numbers of samples are 
handled and where a continuous record of loss in weight with time is required (Milo 
Gibladi,2009) .
1 to 2 gm of sample of metoprolol succinate was accurately weighed and the 
powder was kept in a moisture balance apparatus for 5 min at 106°C and the moisture 
content was calculated.
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Lod(%)= ((initial wt-final wt)/initial wt))*100
(Limit= NMT 0.25%)
Determination of bulk density and tap density
An accurately weighed quantity of the powder (W) was carefully poured into 
the granulated cylinder and volume (Vo) was measured. Then the graduated cylinder 
was closed with lid. Set into the density determination apparatus (bulk density 
apparatus) the density apparatus was set for 500 taps, 750 taps and 1250 taps. After 
that the volume (Vf) was measured and continued the operation till the two 
consecutive reading were equal. The bulk density and the tapped density were 
calculated using the formulas (James, 1999).
                                            Bulk density =  W / Vo
                                                
                                      Tapped density = W / Vf
Where,   W = weight of the powder
  VO = initial volume
  VF = final volume
Compressibility index and Hausner’s ratio
In recent years the compressibility index and the closely related Hausner’s 
ratio have become the simple, fast and popular methods of predicting powder flow 
characteristics. Both the compressibility index and the Hausner’s ratio were 
determined by using bulk density and the tapped density of a powder (Annon et al., 
2004).
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                        % Compressibility    =     ( Pt – PO / Pt )  x 100  
                       
Where,  Pt   =  Tapped density and 
             PO  =  Bulk density
Hausner ratio   =    Tapped density/Bulk density
                   
Table 16: Standard values of Hausner ratio and Compressibilty index
S.No Hausner ratio Compressibilityindex Flow character
1 1.00-1.11 ≤10 Excellent
2 1.12-1.18 11-15 Good
3 1.19-1.25 16-20 Fair
4 1.26-1.34 21-25 Passable
5 1.35-1.45 26-31 Poor
6 1.46-1.59 32-37 Very poor
7 >1.60 >38 Very very poor
Angle of repose
The angle of repose has been used to characterize the flow properties of solids.
Angle of repose is a characteristic related to inter-particulate friction or resistance to 
movement between particles. This is the maximum angle possible between surface of 
pile of powder or granules and the horizontal plane.
Tan  = h/r
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θ = Tan-1 h/r
where, h = height, r = radius and θ = angle of repose.
A funnel was fixed at a height approximately of 2-4 cm over the platform. The
loose powder was slowly passed along the wall of funnel, till the cone of the powder 
formed. Determine the angle of repose by measuring the height of the cone of powder 
and radius of the heap of powder.
Table 17: Standard values of angle of repose
Flow property Angle of repose (degrees)
Excellent 25-30
Good 31-35
Fair-aid not needed 36-40
Passable-may hang up 41-45
Poor-must agitate/vibrate 46-55
Very poor 56-65
Very, very poor >66
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Sieve analysis
The main aim of sieve analysis was to determine the different size of drug 
particles present. Series of standard sieve were stacked one above the other so that the
sieves with larger pore size (less sieve number) occupy top position followed by sieve
of decreasing pore size (large sieve number) towards the bottom.
Procedure
A series of sieves were arranged in the order of their decreasing pore diameter 
(increasing sieve number) i.e. sieve no. 20, 30, 40, 60 100, 120 and 200. 100 gms of 
the drug was weighed accurately and transferred to sieve number 20 which were kept 
on top. The sieves were shaken for about 5-10 minutes then the drug retained on each 
sieve were taken, weighed separately and expressed in terms of percentage.
Compatibility studies by IR
One of the requirements for the selection of suitable excipients or carriers for 
pharmaceutical formulation is its compatibility. Therefore in the present work a study 
was carried out by using infrared spectrophotometer to find out if there is any possible
chemical interaction of Metoprolol Succinate drug with  HPMC and ethylcellulose.
Procedure
Weighed amount of drug (1 mg) was mixed with 99 mg of potassium bromide 
(dried at 40°C - 50oC). The mixture was taken and compressed under 7-ton pressure in
a hydraulic press to form a transparent pellet. The pellet was scanned in IR 
spectrophotometer in the range of 2000 cm-1 to 500 cm-1.
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Drug excipient compatibility study by force degradation method
The compatibility of drug and formulation components is important 
prerequisite before formulation. It is therefore necessary to confirm that the drug does 
not react with the polymers and excipients under experimental conditions and affect 
the shelf-life of product or any other unwanted effects on the formulation.
Procedure
Drug is mixed with excipients in different ration. 15gm of blend is prepared 
which is filled in 3 vials. Observations for physical appearance are made at zero 
weeks, 2 weeks and 4 weeks. These mixtures were kept in a 5ml glass white colored 
vials and packed properly. These vials are exposed to the different conditions 40°C at 
75%RH, 60°C and 2-8°C. The samples are taken at the regular intervals and they are 
tested visually for any color change in the product, if any color change exists then it 
shows that the drug is not compatible with the excipient. Then the excipients have to 
be changed and again should be tested with other excipients to see compatibility 
between them. if any color change does not occur then they can be formulated to form
a formulation. This process continues until we get the compatible excipients with the 
drug. The samples are taken monthly when kept at 40°C, the samples are taken at 
every 15 days when  the samples are kept at 60°C and monthly when the samples are 
kept between 2°-8°C. Then the samples are taken and examined visually for the color 
change.
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4.4 Formulation development
Metoprolol succinate extended release capsules were prepared. The process 
was displayed in the below flow chart. 
Flow chart for manufacturing of extended release capsules
1. Preparation of core pellet
Preparation of core mixture suspension (drug and excipients)
↓
Loading of sugar spheres in to fluid bed coater
↓
Coating of metoprolol succinate
↓
2. Sub Coating
Dissolve the required amount of Ethyl cellulose in Isopropyl alcohol
Stir it for 5 minutes to form uniform solution
↓
Spray the coating solution by using Fluidized bed coater
↓
Maintain the required conditions in coater
↓
Collect #16 passed #20 retained fines
↓
Filling of the pellets into capsules.
Preparation of pellets 
Preparation of core mixture suspension
The required quantities of the drug and the excipients are taken approximately 
and mixed in water. It is stirred until a uniform suspension is formed.
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Preparation of core drug pellets
The non-pariel seeds (sugar spheres 24/30) are accurately weighed and 
transferred into the coating pan. The drug suspension is sprayed on the non-pariel 
seeds at the given set of conditions which are given below. The coating was done by 
the solution layering technique.
Drying of the core drug pellets
Then these pellets are dried at 40-45°C for 6-8 hrs. The moisture content 
should be less than 2% in the pellets. Then the pellets are sifted and passed through 
the sieve and the pellets of size 14/20 are collected and are taken for coating with the 
polymer for sustained release of the drug. 
Preparation of sub coating material
The sub coating material is prepared by dissolving the required quantities of 
the ethyl cellulose in isopropyl alcohol and it is stirred for 15min to form a uniform 
solution. Then this is taken to coat the core drug pellets.
Coating of the core drug pellets
The sub coating solution was sprayed on the core pellets in the fluid bed 
coater. This makes the sustained release layer around the core pellet. The conditions 
which are required for the coating are given below.
Drying of the core drug pellets
The pellets after sub coating are taken and they are dried. Then the pellets are 
taken and are passed through the sieve of required ranges and the required pellets are 
collected. The pellets of size 16/20 are collected.
Filling of core pellets into the capsules
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The obtained pellets are taken and are transferred into the capsule of suitable 
size. each capsule should be with drug equivalent to label claim.
Table 18: Composition of the core pellets in the formulation trials.
S.
No Ingredients (mg)
MSER
CF1
MSER
CF2
MSER
CF3
MSER
CF4
MSER
CF5
MSER
CF6
MSER
CF7
MSER
CF8
1 Metoprolol
succinate 50 50 50 50 50 50 50 50
2 Manitol 12.5 12.5 12.5 12.5 12.5 125 125 12.5
3 Sodium lauryl
sulphate 10 9.5 9 8.5 8 7.5 7 6.5
4 Sugar spheres(24/30) 25 25 25 25 25 25 25 25
5 HPMC 1.5 2 2.5 3 3.5 4 4.5 5
6 Yellow oxide 1 1 1 1 1 1 1 1
Total  (mg) 100 100 100 100 100 100 100 100
Table 19: Composition of the coating material for the optimized core pellet
S.N
o
Ingredients MSER F1
MSER
F2
MSE
R F3
MSE
R F4
MSE
R F5
MSE
R F6
MSE
R F7
MSE
R F8
7 Ethyl cellulose(mg) 2% 2.5% 3% 3.5% 4% 4.5% 5% 5.5%
8 Iso propyl alcohol(ml) 65ml 85ml 100ml 115ml 135ml 150ml 165ml 185ml
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Fluidized bed processor was operated with following conditions
 Inlet temperature - 40-45°C
 Bed temperature - 35-40°C
 Spray rate - 5 rpm
 Air pressure - 1-1.5 pascals 
4.5 Evaluation of drug coated and polymer coated pellets
Description
For checking the appearance of pellets 20 gm of pellets taken From respective 
batch and observed for the color and shape of the pellets
Hardness
Hardness tester was used to determine the hardness of pellets. The test pellet 
was held between the edge of the fixed and movable part of the instrument. The scale 
was adjusted by sliding so that the zero on the scale coincides with the pointer. The 
adjustable knob is slowly moved till the pellet breaks. The pressure indicated on the 
dial was in newtons (N). The hardness test was performed by pharmatest hardness 
tester. After breaking of the pellets the display is read and the reading is noted down.
Flow properties
Determination of bulk density and tap density
An accurately weighed quantity of the powder (W) was carefully poured into 
the granulated cylinder and volume (Vo) occupied by the dry powder is measured. 
From this the bulk density of the sample can be calculated by using the formula given 
below. Then the graduated cylinder was closed with lid. Set into the density 
determination apparatus,  the density apparatus was set for 500 taps, 750 taps and 
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1250 taps. After the procedure for each set of taps the cylinder is taken and the 
volume (Vf) occupied by the dry powder is measured and continued the operation till 
the two consecutive reading were equal. The  tapped density is calculated using the 
formula.
        Bulk density =  W / Vo
                                                
                                      Tapped density = W / Vf
Where, W = weight of the powder
VO = initial volume
Vf = final volume
Compressibility index and Hausner ratio
In recent years the compressibility index and the closely related Hausner ratio 
have become the simple, fast and popular methods of predicting powder flow 
characteristics. Both the compressibility index and the Hausner’s ratio were 
determined by using bulk density and the tapped density of a powder. The formulas 
which are used for calculating the compressibility index and the Hausner’s ratio is 
given below.
                        % Compressibility    =     ( Pt – PO / Pt )  x 100  
                       
Where,  Pt   =  Tapped density and 
             PO  =  Bulk density
Hausner ratio   =    Tapped density/Bulk density
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The standard values for the compressibility index and the Hausner’s ratio is 
given during the discussion of pre-formulation studies of the pure drug
Angle of repose 
The angle of repose has been used to characterize the flow properties of solids.
Angle of repose is a characteristic related to inter-particulate friction or resistance to 
movement between particles. This is the maximum angle possible between surface of 
pile of powder or granules and the horizontal plane.
                                                Tan θ = h/r
θ = Tan-1 h/r
Where, θ = angle of repose, h = height and r = radius.
Procedure
A funnel was fixed at a height approximately of 2-4 cm over the platform. The
loose powder was slowly passed along the wall of funnel, till the cone of the powder 
formed. Determine the angle of repose by measuring the height of the cone of powder 
and radius of the heap of powder.
The standard values for the compressibility index and the Hausners ratio is 
given during the discussion of pre-formulation studies of the pure drug
 Sieve analysis
The main aim of sieve analysis was to determine the different size of drug 
particles present. Series of standard sieve were stacked one above the other so that the
sieves with larger pore size (less sieve number) occupy top position followed by sieve
of decreasing pore size (large sieve number) towards the bottom.
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Procedure
 A series of sieves were arranged in the orde of their decreasing pore diameter 
(increasing sieve number) i.e. sieve no. ASTM 40, 60, 80, 100 with 40gms of drug 
were weighed accurately and transferred to sieve 40 which were kept on top. The 
sieves were shaken for about 5-10min. then the drug retained on each sieve were 
taken, weighed separately and expressed in terms of percentage.
Assay 
Preparation of buffer
6.8 pH Phosphate buffer: dissolve 6.8gm of potassium di-hydrogen phosphate 
in purified water. Make up the volume upto 1000ml by purified water and adjust the 
pH by using sodium hydroxide solution.
Preparation of standard
Aqueous solutions of phosphate buffer of pH 6.8 is prepared as per USP25. 
Standard drug solution was prepared (1 mg/ml) in Phosphate buffer 6.8. Metoprolol 
(100mg) was dissolved in 10 ml of  Phosphate buffer 6.8 and the total volume was 
brought to 100ml with phosphate buffer 6.8 to obtain stock solution. Stock solution 
was further diluted to obtain 5-30 µgm/ml with phosphate buffer 6.8.
Preparation of sample
MS pellets 50mg were transferred into volumetric flask and added upto 50ml 
with pH 6.8 phosphate buffer. The amount of drug content was estimated UV 
spectrophotometrically. Content uniformity test was evaluated for the formulation by 
collecting samples from three different portions of the bulk.
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Dissolution Profile
Buffer preparation 
6.8 pH Phosphate buffer: dissolve 6.8gm of potassium di-hydrogen phosphate 
in purified water. Make up the volume up to 1000ml by purified water and adjust the 
pH by using sodium hydroxide solution.
Standard curve
Preparation of stock solution: Aqueous solutions of phosphate buffer of pH 6.8
is prepared as per USP25. Standard drug solution was prepared (1mg/ml) in 
Phosphate buffer 6.8. Metoprolol (100mg) was dissolved in 10ml of  Phosphate buffer
6.8 and the total volume was brought to 100ml with phosphate buffer 6.8 to obtain 
stock solution.
Stock solution was further diluted to obtain 5-30 µgm/ml with phosphate buffer 6.8. 
Standard solutions of Metoprolol succinate (10µgm/ml) in phosphate buffer is 
scanned in the 200-700nm range to determine the maximum absorbance (λmax). The 
λmax was determined in the solvent and found to be 224nm.
The absorbance was measured at 224nm against phosphate buffer 6.8 as blank.
The calibration curve was plotted in the concentration range of 5-30 µgm/ml of 
Metoprolol succinate in phosphate buffer 6.8 .
In- vitro drug release studies 
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The in vitro drug release studies were performed for marketed product using 
dissolution medium as 6.8 pH Phosphate buffer volume 900 ml at 50 rpm, USP II 
apparatus. By using UV-spectrophotometer at 224 nm.
Dissolution 
The samples are taken from the formulated trial batches. These samples are 
filled in the capsules. Then these capsules are subjected to the in-vitro dissolution 
tests. The samples are taken at specific intervals and the percentage of drug release is 
calculated. Then the cumulative percentage drug release of the different trials are 
compared with that of the Innovator drug release profile. The drug release profile of 
the trial which matches with that of the innovator drug release profile is taken and the 
evaluation tests for this optimized formulation is carried out. The dissolution test is 
carried by considering the following parameters.
Dissolution parameters
 Media - 6.8 pH phosphate buffer.
 Apparatus - USP II (paddle)
 RPM - 50
 Amount of media - 500 ml
 Temperature - 37ºC ±0.5
 Time - Upto 20hrs for polymer coated pellets.
Upto 1hr for drug coated pellets.
4.6 Evaluation of capsules
Weight variation test
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 Individual weights of 20 capsules were taken and the average weight was 
calculated by using the following formula. 
                  (Weight of capsule-Average weight)
Weight variation = ----------------------------------------------- ×100
         Average weight of capsules
Weight variation should not be more than 7.5%.
Disintegration test
The disintegration test is done to know the time needed for the disintegration 
of the capsule shells and to release its components  into the buffer solution. For the 
hard gelatin capsules the disintegration time limit shall not be more than 30mins.
Assay
Preparation of buffer
 6.8 pH Phosphate buffer: dissolve 6.8gm of potassium di-hydrogen phosphate 
in purified water. Make up the volume upto 1000ml by purified water and adjust the 
pH by using sodium hydroxide solution.
Preparation of standard
 Aqueous solutions of phosphate buffer of pH 6.8 is prepared as per USP25. 
Standard drug solution was prepared (1mg/ml) in Phosphate buffer 6.8. Metoprolol 
(100mg) was dissolved in 10ml of  Phosphate buffer 6.8 and the total volume was 
brought to 100ml with phosphate buffer 6.8 to obtain stock solution.Stock solution 
was further diluted to obtain 5-30 µgm/ml with phosphate buffer 6.8.
Preparation of sample
 MS pellets 50mg were transferred into volumetric flask and added upto 50ml 
with pH 6.8 phosphate buffer. The amount of drug content was estimated UV 
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spectrophotometrically. Content uniformity test was evaluated for the formulation by 
collecting samples from three different portions of the bulk.
Loading of metoprolol succinate pellets in capsules
Objective
      The primary objective is to prepare Metoprolol succinate capsules of 25 mg 
strength. This is done by taking Metoprolol succinate core pellets equivalent to 25mg 
of Metoprolol succinate from the formulation MSER F7 and loading into the capsules 
of given appropriate size. The filling of the pellets into the capsules is done by the 
capsule filling machine. Then these are evaluated for the required evaluation tests.
Procedure
1. Size ‘2’ capsules were selected for capsule formulation.
2. The pellets were loaded in hard gelatin capsules No-2 with capsule filling 
machine
3. Coated pellets were transferred into capsules by spreading it into equal 
quantities equivalent to 25 mg Metoprolol succinate.
       
4.7 Kinetics of drug release
The results of in vitro release profiles obtained for all the formulations were 
fitted into three models of data treatment as follows: 
1. Cumulative percent drug released versus time (zero-order kinetic model). 
2. Cumulative percent drug released versus square root of time (Higuchi’s model). 
3. Log cumulative percent drug released versus log time (Korsmeyer-Peppas 
equation). 
Zero Order Kinetics 
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A zero-order release would be predicted by the following equation. 
At = A0 – K0t …1
                      Where, 
                                 At = Drug release at time ‘t’ 
                                 A0 = Initial drug concentration 
                                  K0 = Zero-order rate constant (hr
-1). 
When the data is plotted as cumulative percent drug release versus time, if the 
plot is linear then the data obeys zero-order release kinetics, with a slope equal to K0. 
Higuchi’s Model
 Drug released from the matrix devices by diffusion has been described by 
following Higuchi’s classical diffusion equation. 
Q = [Dε/τ(2A- εCs) CS t] ½ …2
                         Where, 
                                  Q = Amount of drug released at time ‘t’ 
                                  D = Diffusion coefficient of the drug in the matrix 
                                  A = Total amount of drug in unit volume of matrix 
                                 CS = The solubility of the drug in the diffusion medium 
                                   ε = Porosity of the matrix 
                                   τ = Tortuosity 
                                   t = Time (hrs) at which ‘Q’ amount of drug is released. 
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Equation-2 may be simplified if one assumes that D, CS and A are constant. 
Then equation-2 becomes:  
Q = Kt½ …3
When the data is plotted according to equation-3 i.e., cumulative drug released
versus square root of time, yields a straight line, indicating that the drug was released 
by diffusion mechanism. The slope is equal to ‘K’. 
Korsmeyer and Peppas Model
 The release rates from sustained release polymeric matrices can be described 
by the equation (4) proposed by Korsmeyer et al. 
Q = K1t
n 
…. 4
Q is the percentage of drug released at time‘t’, K is a kinetic constant 
incorporating structural and geometric characteristics of the tablets and ‘n’ is the 
diffusional exponent indicative of the release mechanism. 
For Fickian release, n=0.45 while for anomalous (Non-fickian) transport, n ranges 
between 0.45 and 0.89 and for zero order release, n = 0.89.
4.8 Stability studies
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
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environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives.
The International Conference on Harmonization (ICH) guidelines titled 
“Stability Testing of New Drug substance and Products” (QIA) describes the stability 
test requirements for drug registration for drug registration applications in the 
European Union, Japan and The United States of America.
ICH specifies the length of study and storage conditions.
Table 20: Stability Storage Conditions
Study Storage condition
Minimum time period
covered by data at
submission.
Long term 25ºC ± 2 ºC/ 60% RH ±5% RH 12 months
Intermediate 30ºC ± 2 ºC/ 65% RH ±5% RH 6 months
Accelerated 40ºC ± 2 ºC/ 75% RH ±5% RH 6 months
Stability studies were conducted according to ICH Guidelines; the optimized 
formulation was packed and stored at three different conditions i.e. Long term, 
intermediate and accelerated conditions in a stability chamber for a period of 3 
months. The samples were evaluated for assay and dissolution studies at regular 
intervals.
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5. RESULTS AND DISCUSSION
The present study was carried out to formulate Metoprolol succinate ER 
pellets (25 mg). The study involves pre-formulation studies of drug and excipients, 
formulation and processing development along with evaluation of pellets made with 
the optimized formulation. Finally extended release pellets were evaluated by in-vitro 
methods.
5.1 Pre-formulation studies
Table 21: Preformulation studies of Metorpolol succinate pure drug
S.No Characteristics Results
1 Organoleptic evaluation
Color: white crystalline powder
Taste: bitter
Odor: characteristic
2 Solubility analysis
Freely soluble in water, soluble in
methanol, sparingly soluble in ethanol and
slightly soluble in dichloromethane and 2-
propanol, insoluble in ethyl-acetate,
acetone, diethyl ether and heptane.
3 Bulk density 0.375 gm/ml
4 Tapped density 0.5727 gm/ml
5 Compressibility index 34.55
6 Hausner’s ratio 1.528
7 Loss on drying 0.19%
8 Angle of repose (°) 37.23°
The pre-formulation studies are done and the results are given in the above 
table. The flow property studies results showed that the drug has poor flow properties.
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The solubility studies are done and it indicates that the drug is freely soluble in water 
and slightly soluble in alcohol.
Sieve analysis
Table 22: Sieve analysis of Metoprolol succinate pure drug
S.No. Sieve no
Empty
sieve
(mg)
Sample
sieve
(mg)
Difference
(mg) %Retained
%Cumulativ
e retained
1 #20 321.4 321.4 0 0 0
2 #30 328.6 328.8 0.2 0.2 0.2
3 #40 299 300 1 1 1.2
4 #60 287.2 297.4 10.2 10.2 11.4
5 #100 255 275 20 20 31.4
6 #120 274 299 25 25 56.4
7 #200 270 303.2 33.2 33.2 89.6
8 Receiver 348.8 359 10.2 10.2 99.8
Weight of smple = 100gm.
Through this analysis we came to know that as large quantity of powder was 
retained on sieve no. 200, which indicates poor flow of drug. Flow property and 
particle size are inversely proportional to each other as Metoprolol succinate has fine 
grade of particles, it has poor flow. In this process the particle size of the drug is also 
known. But due to the poor flow property of the pure drug  the size of the particles is 
not estimated. 
Drug –polymer compatibility studies by FTIR
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In the compatibility studies by using the FTIR process, the drug is mixed with 
each excipient or polymer mostly in small quantities and they are allowed to react for 
some time as specified. Then the samples from these mixtures are taken and they are 
exposed to the IR spectroscopy. From the peaks that are obtained we can estimate the 
reaction between the drug and its excipients by comparing the FTIR graphs of the 
pure drug and the FTIR graph of the mixture. if any difference is observe then it 
indicates that the drug is not compatible with the excipients and we cannot further 
formulate the formulation using these ingredients. The results showed no major 
difference betweenn the FTIR pure drug graph and the the FTIR graph of the mixture,
so they are said to be compatible with each other and we can further use these 
mixtures in the present study of formulation to formulate the Metoprolol succinate 
pellets. The major peaks in the FTIR spectra of the metoprolol succinate pure drug are
given in the following table
Table 23: Identification peaks of Metoprolol succinate
S. No. Functional group cm-1 (Wave No)
1 0-H bending 1051.24
2 C-0 Aromatic “C” 1242.5
3 C-H aromatic defStretching 781-842.92 3030
4 N-H Stretching 3400-3500 1558.54 – 1616.40
5 C-H alkane Stretch 2850 – 2960 1332.86
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Figure 13: FTIR Spectra of Metoporolol succinate pure drug.
Figure 14: FTIR Spectra of Metoprolol succinate and HPMC
Department of pharmaceutics        85          JKKMMRF college of pharmacy
Chapter 5                                                                                     Results  & discussion
Figure 15: FTIR spectra of Metoprolol succinate and Ethyl cellulose
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Drug-excipients compatibility studies
The drug–excipient compatibility studies are studies at 3 different conditions. 
The 3 different conditions at which the accelerated stability studies are carried out are 
40°C , 75%RH for 3 months
60°C for 30 days
2-8°C for 3 months. 
The samples are withdrawn at regular intervals and evaluated. The results for 
the last samples are given in the following table.
Table 24: Drug-excipient compatibility study of Metoprolol succinate with its
excipients
S.
No
Compositio
n details
Ratio
API:
Expt
Observations
ConclusionStorage condition/duration
Initial
(color)
40°C/7
5%RH 60°C
2-
8°C
3M 30D 3M
1 API ---- White toyellowish NCC NCC NCC Compatible
2 API+
mannitol 1:1
A white
color
powder
NCC NCC NCC Compatible
3
API+
sodium
lauryl
sulphate
1:1
A white
color
powder
NCC NCC NCC Compatible
4 API+ sugar
spheres 1:1
A white
color
powder
NCC NCC NCC Compatible
Department of pharmaceutics        87          JKKMMRF college of pharmacy
Chapter 5                                                                                     Results  & discussion
5 API+HPMC 1:1
A white
color
powder
NCC NCC NCC Compatible
6
API+
yellow
oxide
1:1
A white
color
powder
NCC NCC NCC Compatible
7 API+ ethyl
cellulose 1:1
A white
color
powder
NCC NCC NCC Compatible
NCC = No Color Change
By studying the Drug-excipient compatibility studies and IR spectra’s the 
results showed that there was no interaction between the drug and its excipients, so 
the excipients were found to be compatible with the drug (Metoprolol succinate).
5.2 Evaluation of drug coated pellets (core pellets)
The sample of pellets were taken after the coating of the sugar spheres with 
the drug suspension. Then these were evaluated for shape and color visually.
Table 25: Physical characters of Metoprolol succinate optimized core pellets
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S.No. Characteristics Results
1. Physical appearance Yellowish crystalline spheres.
2. Dimension 1.2µ-1.8µ
3. Hardness 6N
3. Bulk density 0.38 gm/ml
4. Tapped density 0.448 gm/ml
5. Compressibility index 15.147%
6. Hausner’s ratio 1.178%
7 Angle of repose 33.47°
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By studying the pre-formulation studies of the coated pellets, the results 
showed that the flow properties of the pellets are not good in the formulations MSER 
CF1 but as the concentration of HPMC increased the flow property was good. And 
there is no need to add an excipient to increase the plow properties. But in the 
formulation MSER CF8 the pellets showed cracks so the formulation MSER CF7 was
optimized. The pellets after the formulation showed Yellowish color due to the 
addition of the coloring agent.
Sieve analysis
Table 26: Particle size distribution of Metoprolol succinate core pellets
S.N
o
Sieve
numbe
r
MSE
R CF1
(mg)
MSE
R CF2
(mg)
MSE
R CF3
(mg)
MSE
R CF4
(mg0)
MSE
R CF5
(mg)
MSE
R CF6
(mg)
MSE
R CF7
(mg)
MSE
R CF8
(mg)
1 10 12.2 20.6 10.4 8.6 4.3 1.2 0 0
Department of pharmaceutics        89          JKKMMRF college of pharmacy
Chapter 5                                                                                     Results  & discussion
2 12 36.2 37.2 32.1 36.3 39.1 13.3 1.4 0.6
3 16 33.4 32 31.4 18 15.3 3.2 `2.4 1.2
4 18 12 10.2 26.1 47.1 63.3 83.3 96.2 98.2
The sieve analysis has been performed to check the size of the coated pellets, 
and the results revealed that the pellets are of uniform in size and they are in the size 
of 1.2µ - 1.8µ. The size of the pellets is determined by identifying the sieve which has
allowed the pellets to pass and the sieve on which the sample is collected.  The Sieve 
that has retained the pellets determines the minimum size of the pellets and the sieve 
which has allowed the pellets to pass determines the maximum size of the pellets. 
These results indicated that the formulations with more binder (HPMC) concentration 
showed better flow properties and uniform size. In the MSER CF1 the pellets were 
agglomerated and there was poor flow. As the concentration of the binder (HPMC) 
was increased and the concentration of the wetting agent was decreased (SLS) the 
agglomeration of the pellets were decreased and the flow properties of the pellets 
were increased. The formulation MSER FC7 showed best flow properties among all 
the formulations.
Assay of pellets
Table 27: Assay of core pellets
Characte
r
MSER
CF1
MSER
CF2
MSER
CF3
MSER
CF4
MSER
CF5
MSER
CF6
MSER
CF7
MSER
CF8
Assay 98.56% 97.68% 98.36% 97.34% 98.64% 98.48% 99.32% 98.86%
The assay is conducted to check the purity of the sample or drug. In this test 
the pellets are tested for the content of the drug present in the pellets and to check 
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whether the drug is present according to label claim in the pellets. The results revealed
that the drug content is present with in the limits of the label claim that are specified 
for all the formulations.
Dissolution studies
The samples are taken from the formulated trial batches. These samples are 
filled in the capsules. Then these capsules are subjected to the in-vitro dissolution 
tests. The samples are taken at specific intervals and the percentage of drug release is 
calculated. The drug release profile of the trial which matches with that of the 
innovator drug release profile is taken and the evaluation tests for this optimized 
formulation is carried out. The dissolution test is carried by considering the following 
parameters.
Dissolution parameters
 Media - 6.8 pH phosphate buffer
 Apparatus - USP II (paddle)
 RPM - 50
 Amount of media - 500ml
 Temperature - 37ºC ±0.5
 Time - Upto 1hr.
 Time interval - 10min.
Table 28: Dissolution studies of drug coated pellets (core pellets)
S.N
o
Time
interva
l (min)
Cumulative % drug release
MSE
R CF1
MSE
R CF2
MSE
R CF3
MSER
CF4
MSE
R CF5
MSE
R CF6
MSE
R CF7
MSER
CF8
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1 15 38.75 36.85 33.86 31.48 27.85 26.89 25.36 24.48
2 30 78.46 75.86 74.84 68.78 58.78 55.35 64.86 56.56
3 45 98.56 98.84 95.46 93.85 88.46 83.42 82.73 81.56
4 60 99.65 99.32 98.76 98.82 99.45 99.64 99.65 98.87
The dissolution studies for the drug coated pellets were conducted according 
to the in house specifications. the results showed that all the formulations released the 
drug with in one hour. The MSER CF1 released the drug with in 45min because of the
more amount of the wetting agent (SLS) in it. as the SLS concentration decreased and 
binder (HPMC) concentration increased in the further formulations the drug released 
was retarded to a smaller extent.
By considering all the evaluation results the formulation with 7% Sodium 
lauryl sulphate (SLS) and 4.5% binder (HPMC) was optimized. Then these pellets 
were given polymer coating in varied proportions by using ethyl cellulose as drug 
release retardant polymer.
5.3 Evaluation of polymer coated pellets
Table 29: Physical characters of optimized Metoprolol succinate polymer coated
pellets
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S.No. Characteristics Results
1. Physical appearance Yellowish crystalline powder.
2. Dimension 1.6nm-2nm
3. Hardness 9N
3. Bulk density 0.37gm/ml
4. Tapped density 0.425gm/ml
5. Compressibility index 11.793%
6. Hausner’s ratio 1.1317%
7 Angle of repose 28.53
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By studying the pre-formulation studies of the coated pellets, the results 
showed that the flow properties of the pellets are good. And there is no need to add an
excipient to increase the flow properties. The pellets after the formulation showed 
Yellowish color due to the addition of the coloring agent.
Sieve analysis
Table 30: Particle size distribution polymer coated pellets
S.N
o
Sieve
numbe
r
MSE
R F1
(mg)
MSE
R F2
(mg)
MSE
R F3
(mg)
MSE
R F4
(mg)
MSE
R F5
(mg)
MSE
R F6
(mg)
MSE
R F7
(mg)
MSE
R F8
(mg)
1 12 0 0 0 0 0 0 0 0
2 16 8.4 7.9 2.5 1.9 1.4 4.5 2.06 2.07
3 18 3.4 2.8 1.4 1 0.97 1.6 2.48 1.45
4 20 88.2 89.3 96.1 98.03 97.8 93.39 95.46 96.48
The sieve analysis has been performed to check the size of the coated pellets, 
and the results revealed that the pellets are of uniform in size and they are in the size 
of 16µ - 20µ. The size of the pellets is determined by identifying the sieve which has 
allowed the pellets to pass and the sieve on which the sample is collected.  The Sieve 
that has retained the pellets determines the minimum size of the pellets and the sieve 
which has allowed the pellets to pass determines the maximum size of the pellets. By 
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the results from the sieve analysis the it has been found that the pellets has improved 
flow properties and they did not agglomerate like the drug coated pellets. These also 
showed uniform particle size in all the formulations which indicates the uniform 
coating of the polymer on the drug coated pellets.
Assay of pellets
Table 31: Assay of polymer coated pellets
Characte
r
MSER
F1
MSER
F2
MSER
F3
MSER
F4
MSER
F5
MSER
F6
MSER
F7
MSER
F8
Assay 99.45%
99.78
%
100.43
%
99.65
%
99.86
%
99.48
%
99.86
%
99.48
%
The assay is conducted to check the purity of the sample or drug. In this test 
the pellets are tested for the content of the drug present in the pellets and to check 
whether the drug is present according to label claim in the pellets. The results revealed
that the drug content is present with in the limits of the label claim that are specified 
for all the formulations.
Dissolution profile
Standard graph for metoprolol succinate 
Table 32: Standard plot of Metoprolol succinate
S.No Concentratio
n (µgm/ml)
Absorbanc
e
1 5 0.172
2 10 0.328
3 15 0.476
4 20 0.662
5 25 0.791
6 30 0.9696
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Figure 16: Standard curve of metoprolol succinate
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In-vitro dissolution test
The dissolution was carried out for different experimental trials and also for 
the innovator. The various results that are obtained are tabulated below. The procedure
for the dissolution is already given tin the materials and methods part. Dissolution 
studies are carried out in the following media.
Medium : phosphate buffer ph 6.8
Apparatus : USP type II (paddle)
RPM : 50
Volume : 500 ml
Temperature : 37±0.5ºC
Time : 20 hrs
The different formulations are made by varying the concentrations of the 
coating material. The core material is made up of the sugar spheres and this is coated 
by the core drug suspension which consists of the Active Pharmaceutical Ingredient 
along with the excipients like the mannitol, hydroxy propyl methyl cellulose,  sodium 
lauryl sulphate, yellow oxide. Then this solution is coated unto the pellets. The sub 
coating material constituting of ethyl cellulose which is dissolved in isopropyl alcohol
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is coated on the drug coated pellets. In the MSER F1 the ethyl cellulose coated was 
2%  and the dissolution profile for the MSER F1 pellets are observed. The results 
showed immediate drug release from the formulated pellets, that indicates that the 
retardant is very low in the MSER F1 formulation.
In the MSER F2 the coating material is increased to increase the retardant 
capacity of the pellets. The ethyl cellulose concentration was increased to 2.5%. Then 
these are evaluated for the dissolution test. the results reveled that the drug release in 
the first hour is much higher than the specified by the limits so this formulation is also
discarded.
In the MSER F3, the product is formulated with more amount of the coating 
polymer to be coated on the core drug pellets. The polymer concentration was further 
increased to 3%. In this formulated pellets the dissolution profile showed better 
results compared to the old formulations which indicate that by increasing the 
quantity of the retardant or the polymer the drug release is delayed further. But these 
dissolution results does not comply with that of the limits specified in the first hour of 
the drug release, so this formulation is also discarded. then the next formulation is 
taken by further increasing the amount of the retardant.
In the MSER F4 the core pellets are coated with still more polymer compared 
to that of the MSER F3. In this the polymer concentration was increased to 3.5%. 
When these polymer coated pellets are evaluated for the dissolution profile, the results
showed better drug release compared to that of the older formulations and also the 
drug release was in the limits specified for the drug release. But still the drug release 
does not comply with the Innovator drug release, so another formulation is made.
In MSER F5 the polymer concentration was further increased to 4% and the 
formulated pellets were evaluated for the drug release. The results showed a little 
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increase in the drug release but the dissolution results were not satisfactory and does 
not comply with the in house specifications. So another formulation was made by 
further increasing the concentration of the polymer.
In MSER F6 the polymer concentration was 4.5% and the dissolution results 
of these coated pellets showed a further more increase in the delay of the drug release 
but it was not satisfactory and does not comply with the in house specifications. But 
the results were nearer to the innovator drug release pattern.
 In the MSER F7 the amount of the polymer is till increased to retard the drug 
release still further so that the drug release of the formulated drug complies with that 
of the Innovator drug release. The polymer concentration used in this formulation is 
5%. After the formulation of the pellets the sample is taken and have been under gone 
for the dissolution studies. the results have shown very close drug release patterns 
when compared to that of the Innovator drug release pattern. but still further another 
formulation is taken by slightly increasing the polymer.
In MSER F8 the polymer content is still increased to further retard the dug 
release, the polymer content is only slightly increased. The polymer concentration was
increased to 5.5%. Then after coating the samples are taken from the formulation and 
are evaluated for the drug release. The dissolution results showed more delayed drug 
release than the specified limits.
Table 33: Comparative dissolution profile for Metoprolol succinate prepared
formulations MSER F1 to MSER F8.
S.No
Cumulative % drug release
1st hr 4th hr 8th hr 20th hr
MSER F1 48.5 72.3 92.4 99.8
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MSER F2 41 69.83 86 98.67
MSER F3 36.5 57.67 83 98
MSER F4 29.4 52.6 79.4 97.9
MSER F5 26.83 47.5 76 97.83
MSER F6 21 37.67 69.167 98.167
MSER F7 13.83 33.67 56.67 97.33
MSER F8 8.67 27 47 94.5
Figure 17: Comparative dissolution profile for prepared formulations MSER F1
to MSER F8.
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Table 34: Comparitive dissolution profile of MSER F7 and Innovator
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Figure 18: Comparative dissolution profile of MSER F7 and Innovator
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When the drug release patterns of the different formulations and that of the 
Innovator are compared, it showed that the MSER F7 formulation complies better 
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S.No Time (hrs)
Cumulative % drug release
Innovator MSER F7
1 1 15.33 13.83
2 4 34.16 33.67
3 8 57.833 56.67
4 20 96.667 97.33
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with that of the Innovator drug release. So the MSER F7 pellets are optimized and the
evaluation tests like the floe properties, compressibility properties, assay, and other 
evaluation tests are done. 
After all the evaluation tests are done and by examining the results MSER F7 
showed better results compared with all the other formulations, so the MSER F7 
formulation is optimized and it also showed better dissolution results when compared 
with the innovator and complies with the innovator dissolution profile.
5.4 Characteristics of pellets for MSER F7 optimized batch.
Description
The prepared pellets are taken and they are examined visually for the the 
organoleptic characteristics and the pellets were found to be yellow in color, with 
spherical shape.
Hardness
Hardness of the pellets was found to be in the range of 6N to 8N and is given 
in the following table. It is determined by pharmatest hardness tester.
Table 35: Hardness of Metoprolol succinate pellets of different formulations.
Parameter MSERF1
MSER
F2
MSER
F3
MSER
F4
MSER
F5
MSER
F6
MSER
F7
MSER
F8
Hardness(N) 6 8 6 7 6 7 6 8
5.5 Loading of coated pellets and evaluation of capsules
The present study was undertaken to formulate and evaluate Metoprolol 
succinate extended release capsules. Formulation and processing development along 
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with evaluation of the capsules made with the optimized formulation. Results and 
discussion of the above studies are presented below. The optimized pellets equivalent 
to 25 mg of the metoprolol succinate drug is transferred into the pellets of 2 size. The 
average weight of the size 2 pellets is 64 mg.
Table 36: Compilations of capsules (mg/capsules)
S.No Physicalparameter
MSER
F1
MSER
F2
MSER
F3
MSER
F4
MSER
F5
MSER
F6
MSER
F7
MSE
R F8
1 MS(ER)pellets 25mg 25mg 25mg 25mg 25mg 25mg 25mg 25mg
2
Hard gelatin
capsules (size
2)
1 1 1 1 1 1 1 1
3 Talc (mg) 1 1 1 1 1 1 1 1
5.6 Evaluation of capsules 
Table 37: Evaluation of pellets loaded in capsules
S.No Physicalparameter
MSE
R F1
MSE
R F2
MSE
R F3
MSE
R F4
MSE
R F5
MSE
R F6
MSE
R F7
MSE
R F8
1 Weight
variation (mg) 124 132 138 142 147 153 158 162
2 Assay % (99-101%)
100.3
6 99.84 99.25 99.68 99.89 99.45 99.78 99.68
3 Content
uniformity % 100.6 100.2 100.9 99.6 99.7 99.5 100.8 100.6
4 Disintegrationtime
8min
45sec
9min
23sec
9min
45sec
9min
56sec
10min
12sec
10min
23sec
10min
45sec
10min
48sec
The evaluation studies for capsules loaded with the pellets have been carried 
out and the results have been given in the above table. By studying the above results it
shows that the pellets are uniformly filled into the capsules. The assay results and 
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uniform content results reveal that the drug is uniformly coated into the pellets and 
each capsule contain equal amount of the drug in them. The disintegration tests also 
reveal that the capsules disintegrate immediately and releases the pellets into the 
gastro intestinal tract.
5.7 In-vitro Release kinetics
Data of in vitro drug release were fit into different equations and kinetic 
models to explain the release kinetics of Metoprolol succinate from the extended 
release pellet. The kinetic models used were a Zero-order equation, Higuchi’s model 
and Peppa’s models. The obtained results in these formulations were plotted in 
various model treatment are as follows. I.e. Cumulative percentage drug release Vs 
Square root of time (Higuchi’s) and Log cumulative percentage release Vs Log time 
(Peppa's). To know the mechanism of drug release from extended release pellet, the 
drug release data was fit into Higuchi’s models. 
Mechanism of drug release
To find out the mechanism of drug release from hydrophilic pellets, the in 
vitro dissolution data of each formulation with different kinetic drug release 
equations. Namely Zero order: Q=K0t; Higuchi’s square rate at time: Q=KHMSER 1/2 
and Peppa’s: F=Kmtn, where Q is amount of drug release at time t, F is Fraction of 
drug release at time t, K0 is zero order kinetic drug release constant, KH is Higuchi’s 
square root of time kinetic drug release constant, Km is constant incorporating 
geometric and structural characteristic of tablet and n is the diffusion exponent 
indicative of the release mechanism. The correlation coefficient values (R) indicate 
the kinetic of drug release was zero order and the mechanism of drug release by 
Peppa’s model indicates the non fickian evidenced with diffusion.
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Table 38: In-Vitro Drug Release kinetics for MSER 7
S.No
Zero order data Higuchi’s data Peppa’s data
Time
(hrs)
Cummulative
% release
Square
root of
time
Cummulative
% release
Log
time
Log
cummulative
% release
1 0 0 0 0 0 0
2 1 13.83 1 13.83 0 1.140
3 4 33.67 2 33.67 0.602 1.527
4 8 56.67 2.83 56.67 0.903 1.753
5 20 96.667 4.47 96.667 1.301 1.985
Figure 19: Zero order plot of MSER F7
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Figure 20: Higuchi’s plot of MSER F7
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Figure 21: Peppa’s plot of MSER F7
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The In vitro release studies have been done and the results are incorporated
into the zero order plot, Higuchi’s plot and peppa’s plot. All the plots showed that the
drug release follows the zero order kinetics and thus the drug release from the dosage
form is said to be of controlled drug release and it comes under the class extended
release formulations.
5.8 Stability studies
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 The stability studies were carried out according to ICH guidelines for 
optimized formulation i.e. MSER F7. The stability studies were carried out under 3 
conditions i.e. Long term stability (25±20C/60% ±5% RH),Intermediate(30±20C/65% 
±5%)and Accelerated stability studies (40±20C/75% ±5% RH). Then the pellets were 
stored under 3 conditions and the samples were withdrawn at every one month and 
evaluate the pellet parameters like description, assay and dissolution. 
Sample were collected at an interval of 1, 2 and 3rd  months and evaluated. 
Description, Assay and dissolution profile of MSER F7 stored  at three conditions  in 
1M, 2M and 3M samples  were found to be similar with that of  initial samples and 
the results are given below.
Table 39: Physical evaluation of stability studies for optimized MSER F7
at different conditions carried out for 3 months duration.
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Test Month Description Assay
250C/60%RH
(long term)
1 White to off white color 99.8
2 White to off white color 99.67
3 White to off white color 99.61
300C/ 65%RH
(Intermediate)
1 White to off white color 98.45
2 White to off white color 98.37
3 White to off white color 97.91
400C/ 75%RH
(Accelerated)
1 White to off white color 98.23
2 White to off white color 98.05
3 White to off white color 97.86
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When significant changes does not occur at any time during 6 months testing 
at the accelerated storage conditions, additional testing at the intermediate storage 
condition should be conducted and evaluated tests for assay, content uniformity and 
dissolution studies.
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Test Month
Cumulative % drug release (time in
Hrs)
1 4 8 20
250C/60%RH
(long term)
1 13.33 33.167 53.833 93.667
2 13.83 33.67 56.67 97.33
3 12.98 32.65 54.67 95.833
300C/ 65%RH
(Intermediate)
1 13.75 33.59 56.59 97.13
2 13.71 33.55 56.55 96.89
3 13.65 33.48 56.51 96.73
400C/ 75%RH
(Accelerated)
1 13.67 33.51 56.53 97.01
2 13.61 33.44 56.49 96.75
3 13.55 33.29 56.41 96.45
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6. SUMMARY AND CONCLUSION
 Metoprolol succinate is used in the treatment of hyper tension, angina pectoris
(chest pain) and myocardial infarction.  The study was undertaken with an aim
to formulate Metoprolol succinate extended release pellets.
 Before going to develop the formulation a detail product literature review was
carried out to know about the MUPS and type of dosage form available in
market. The present study was focused to formulate extended release capsule
by MUPS Technique. 
 The drug excipient compatibility studies were also conducted and the results
showed that  there  was  no significant  interaction between  the  drug and the
excipients.  The powder showed good solubility in water and also other
solvents. The angle of repose of the powder was found to be 37.23°. The
bulk density, tapped density, compressibility index and hausner’s ration
was  found  to  be  0.375  gm/ml,  0.5727  gm/ml,  34.55  and  1.528
respectively. It showed poor flow properties.
 The  different  formulations  were  made  mainly  by  using  the  different
proportions of the excipients in both the primary and the secondary coating.
The primary coating consists of the API,  diluent, wetting agent and binder,
and the secondary coating consists of the polymer coating.
 The sugar spheres were taken into the fluidized bed coater and the required
amount of drug suspension (primary coating) was taken and coated unto them.
The best  trial  was  selected  by conducting the  evaluation  tests.  The  results
showed that as the concentration of the wetting agent (SLS) in decreased and
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as  the  concentration  of  the  binder  (HPMC)  is  increased  the  pellets  were
formed satisfactorily and they also showed good flow properties. 
 The optimized batch MSER CF7 is made up of 7% wetting agent and 4.5%
binder. The evaluation tests that were conducted for the pellets also showed
satisfactory results.
 These optimized drug coated pellets were taken for the secondary coating i.e.
polymer  coating.  The polymer was coated in varied concentrations  and the
optimized formulation for polymer coating was identified. 
 The formulation MSER F1 showed 48.5% drug release of the drug by the end
of 1st hour. The formulation MSER F2 showed almost 70% drug release by the
end of 4th  hour. The formulation MSER F3, MSER F4 and MSER F5 showed
drug release of 57.67, 52.6 and 47.5% of drug release by the end of 4th hour
respectively.  The  drug  release  was  further  extended  by  increasing  the
concentration of the polymer. In the formulation MSER F6 the drug release
was satisfactory but does not comply with that of the innovator drug release.
The MSER F7 showed better results and the dissolution profile complies with
that of the innovator drug release.  It  showed 97.33% of drug release in 20
hours. The MSER F8 showed still more further decrease in drug release,  it
showed only 8.67% of drug release in the 1st hour and 94.5% of drug release in
20 hours, so the formulation MSER F7 was optimized. The optimized coating
consists of 5% of ethyl cellulose, 7.5% of Sodium lauryl sulphate and 4.5% of
Hydroxy propyl methyl cellulose.
 The best trial was optimized by comparing the drug release profile with the
innovator  and  the  MSER F7  showed  better  results  compared  to  the  other
formulations and the evaluation studies were conducted for the MSER F7.  It
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showed good results in formulation of stable dose.
 The  pellets  were  evaluated  for  the  flow  properties,  sieve  analysis  and
accelerated  stability  studies  for  3months.  The  pellets  showed  good  flow
properties and also showed uniform size which indicates uniform coating.
 The  stability  of  the  capsules  and  pellet  was  determined  by  conducting
“Accelerated stability testing” in 40°C ± 2°C / 75% ± 5%RH and 25ºC ± 2 ºC/
60% RH ± 5% RH conditions for 3 months as per ICH guidelines.  Finally
after the duration, the product was analyzed for assay, content uniformity and
dissolution study. By the stability studies, the formulated metoprolol succinate
extended release capsules and pellets proved to be stable throughout the period
of the storage.
 The dissolution results after the long term (250C/60%RH), intermediate 
(300C/ 65%RH) and accelerated (400C/ 75%RH) were found to be equal to 
that of the optimized formulation (MSER F7).
 The In  vitro drug release  kinetic studies  were  conducted  and the data was
plotted for  zero order,  Higuchi’s  plot  and pepp’s  plot  and the graphs were
plotted.  The  graphs  showed  that  the  drug  release  was  of  zero  order.  The
mechanism of drug release was fount to be diffusion and dissolution and it
indicates  non  fickian  diffusion.  The drug  release  was  found to  be  of  zero
order.
 Extended release pellets have minimum volume in size, greater surface area
and more surface activity. The area of the drug loaded pellets release rate was
also more. And also there was no need of disintegration time for pellets in
capsules. The risk of accumulation of the drug in the body is less. Drug release
rate was more when compared with the innovator sample.
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 Finally  we  concluded  that  the  Metoprolol  succinate  pellets  MSER F7  are
prepared  and  these  showed  good  physico-chemical  properties  and  the
dissolution  results  showed  satisfactory  results  when  compared  with  the
innovator drug.
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